WO2012127464A2 - Lymphocytes t constitutivement activés pour l'utilisation dans une thérapie cellulaire adoptive - Google Patents
Lymphocytes t constitutivement activés pour l'utilisation dans une thérapie cellulaire adoptive Download PDFInfo
- Publication number
- WO2012127464A2 WO2012127464A2 PCT/IL2012/000125 IL2012000125W WO2012127464A2 WO 2012127464 A2 WO2012127464 A2 WO 2012127464A2 IL 2012000125 W IL2012000125 W IL 2012000125W WO 2012127464 A2 WO2012127464 A2 WO 2012127464A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- linked
- peptide
- transmembrane
- seq
- Prior art date
Links
- 210000001744 T-lymphocyte Anatomy 0.000 title claims abstract description 206
- 238000011467 adoptive cell therapy Methods 0.000 title description 31
- 210000004027 cell Anatomy 0.000 claims abstract description 114
- 102000004127 Cytokines Human genes 0.000 claims abstract description 100
- 108090000695 Cytokines Proteins 0.000 claims abstract description 100
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 91
- 239000002157 polynucleotide Substances 0.000 claims abstract description 91
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 91
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims abstract description 75
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims abstract description 75
- 108020001507 fusion proteins Proteins 0.000 claims abstract description 73
- 102000037865 fusion proteins Human genes 0.000 claims abstract description 73
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 claims abstract description 72
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 68
- 102100039360 Toll-like receptor 4 Human genes 0.000 claims abstract description 67
- 108091008035 T cell costimulatory receptors Proteins 0.000 claims abstract description 33
- 201000011510 cancer Diseases 0.000 claims abstract description 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 141
- 108010038807 Oligopeptides Proteins 0.000 claims description 87
- 102000015636 Oligopeptides Human genes 0.000 claims description 87
- 108010002350 Interleukin-2 Proteins 0.000 claims description 74
- 102000000588 Interleukin-2 Human genes 0.000 claims description 74
- 230000001086 cytosolic effect Effects 0.000 claims description 62
- 239000012528 membrane Substances 0.000 claims description 60
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 50
- 150000001413 amino acids Chemical class 0.000 claims description 45
- 229920001184 polypeptide Polymers 0.000 claims description 44
- 108010065805 Interleukin-12 Proteins 0.000 claims description 43
- 102000013462 Interleukin-12 Human genes 0.000 claims description 43
- 210000000170 cell membrane Anatomy 0.000 claims description 41
- 102000003812 Interleukin-15 Human genes 0.000 claims description 35
- 108090000172 Interleukin-15 Proteins 0.000 claims description 35
- 238000000034 method Methods 0.000 claims description 33
- 108090000623 proteins and genes Proteins 0.000 claims description 31
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 claims description 31
- 101150013553 CD40 gene Proteins 0.000 claims description 30
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 29
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 27
- 201000001441 melanoma Diseases 0.000 claims description 23
- 102000025850 HLA-A2 Antigen Human genes 0.000 claims description 22
- 108010074032 HLA-A2 Antigen Proteins 0.000 claims description 22
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 20
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 claims description 19
- 150000007523 nucleic acids Chemical group 0.000 claims description 19
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims description 18
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims description 18
- 239000000203 mixture Substances 0.000 claims description 18
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 17
- 239000013604 expression vector Substances 0.000 claims description 17
- 238000001338 self-assembly Methods 0.000 claims description 17
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 16
- 101100107610 Arabidopsis thaliana ABCF4 gene Proteins 0.000 claims description 15
- 101100068078 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) GCN4 gene Proteins 0.000 claims description 15
- 102000050627 Glucocorticoid-Induced TNFR-Related Human genes 0.000 claims description 13
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 13
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 13
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 claims description 13
- 101710187882 Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims description 13
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 13
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 12
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 12
- 230000011664 signaling Effects 0.000 claims description 11
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 10
- 230000000139 costimulatory effect Effects 0.000 claims description 10
- 238000000338 in vitro Methods 0.000 claims description 10
- 150000003904 phospholipids Chemical class 0.000 claims description 10
- 102100027207 CD27 antigen Human genes 0.000 claims description 9
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 9
- 108091006116 chimeric peptides Proteins 0.000 claims description 8
- 230000004568 DNA-binding Effects 0.000 claims description 7
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims description 7
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims description 7
- 101001055157 Homo sapiens Interleukin-15 Proteins 0.000 claims description 6
- 101000648507 Homo sapiens Tumor necrosis factor receptor superfamily member 14 Proteins 0.000 claims description 6
- 102000056003 human IL15 Human genes 0.000 claims description 6
- 101100099884 Homo sapiens CD40 gene Proteins 0.000 claims description 5
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims description 5
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims description 5
- 238000001514 detection method Methods 0.000 claims description 5
- 102000045717 human TLR4 Human genes 0.000 claims description 5
- 210000000822 natural killer cell Anatomy 0.000 claims description 5
- -1 4-lBB (CD137) Proteins 0.000 claims description 4
- 238000013518 transcription Methods 0.000 claims description 4
- 230000035897 transcription Effects 0.000 claims description 4
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 claims description 3
- 108091008034 costimulatory receptors Proteins 0.000 claims description 3
- 230000001902 propagating effect Effects 0.000 claims description 3
- 210000004881 tumor cell Anatomy 0.000 claims description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 201000009030 Carcinoma Diseases 0.000 claims description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 2
- 206010061968 Gastric neoplasm Diseases 0.000 claims description 2
- 206010019695 Hepatic neoplasm Diseases 0.000 claims description 2
- 208000017604 Hodgkin disease Diseases 0.000 claims description 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 2
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims description 2
- 101000679851 Homo sapiens Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 2
- 208000005016 Intestinal Neoplasms Diseases 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 2
- 210000001185 bone marrow Anatomy 0.000 claims description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 2
- 230000000762 glandular Effects 0.000 claims description 2
- 102000047758 human TNFRSF18 Human genes 0.000 claims description 2
- 102000050320 human TNFRSF4 Human genes 0.000 claims description 2
- 210000000936 intestine Anatomy 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 claims description 2
- 210000001165 lymph node Anatomy 0.000 claims description 2
- 201000000638 mature B-cell neoplasm Diseases 0.000 claims description 2
- 208000010915 neoplasm of mature B-cells Diseases 0.000 claims description 2
- 210000000496 pancreas Anatomy 0.000 claims description 2
- 210000002307 prostate Anatomy 0.000 claims description 2
- 210000002784 stomach Anatomy 0.000 claims description 2
- 210000001550 testis Anatomy 0.000 claims description 2
- 210000001541 thymus gland Anatomy 0.000 claims description 2
- 230000003606 oligomerizing effect Effects 0.000 claims 1
- 238000011282 treatment Methods 0.000 abstract description 12
- 238000012546 transfer Methods 0.000 abstract description 6
- 108020004999 messenger RNA Proteins 0.000 description 43
- 239000012636 effector Substances 0.000 description 32
- 230000004913 activation Effects 0.000 description 31
- 230000000694 effects Effects 0.000 description 29
- 239000003446 ligand Substances 0.000 description 29
- 238000001890 transfection Methods 0.000 description 29
- 108010074328 Interferon-gamma Proteins 0.000 description 28
- 102100037850 Interferon gamma Human genes 0.000 description 27
- 230000014509 gene expression Effects 0.000 description 24
- 102000002689 Toll-like receptor Human genes 0.000 description 23
- 108020000411 Toll-like receptor Proteins 0.000 description 23
- 102000008228 Toll-like receptor 2 Human genes 0.000 description 20
- 108010060888 Toll-like receptor 2 Proteins 0.000 description 20
- 238000013459 approach Methods 0.000 description 17
- 102000004169 proteins and genes Human genes 0.000 description 17
- 230000002068 genetic effect Effects 0.000 description 16
- 239000000427 antigen Substances 0.000 description 15
- 102000036639 antigens Human genes 0.000 description 15
- 108091007433 antigens Proteins 0.000 description 15
- 238000002474 experimental method Methods 0.000 description 15
- 108091008874 T cell receptors Proteins 0.000 description 13
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 13
- 238000009396 hybridization Methods 0.000 description 13
- 210000004698 lymphocyte Anatomy 0.000 description 13
- 238000004519 manufacturing process Methods 0.000 description 13
- 230000000259 anti-tumor effect Effects 0.000 description 12
- 210000000612 antigen-presenting cell Anatomy 0.000 description 12
- 230000015654 memory Effects 0.000 description 12
- 210000003289 regulatory T cell Anatomy 0.000 description 12
- 230000004083 survival effect Effects 0.000 description 12
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 11
- 210000004443 dendritic cell Anatomy 0.000 description 11
- 230000006870 function Effects 0.000 description 11
- 102000039446 nucleic acids Human genes 0.000 description 11
- 108020004707 nucleic acids Proteins 0.000 description 11
- 239000013598 vector Substances 0.000 description 11
- 239000002158 endotoxin Substances 0.000 description 10
- 239000005090 green fluorescent protein Substances 0.000 description 10
- 229920006008 lipopolysaccharide Polymers 0.000 description 10
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 10
- 230000001629 suppression Effects 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 238000001727 in vivo Methods 0.000 description 9
- 230000001404 mediated effect Effects 0.000 description 9
- 230000004044 response Effects 0.000 description 9
- 230000003213 activating effect Effects 0.000 description 8
- 230000004931 aggregating effect Effects 0.000 description 8
- 210000003162 effector t lymphocyte Anatomy 0.000 description 8
- 238000004520 electroporation Methods 0.000 description 8
- 239000001963 growth medium Substances 0.000 description 8
- 230000035755 proliferation Effects 0.000 description 8
- 102000005962 receptors Human genes 0.000 description 8
- 108020003175 receptors Proteins 0.000 description 8
- VDABVNMGKGUPEY-UHFFFAOYSA-N 6-carboxyfluorescein succinimidyl ester Chemical compound C=1C(O)=CC=C2C=1OC1=CC(O)=CC=C1C2(C1=C2)OC(=O)C1=CC=C2C(=O)ON1C(=O)CCC1=O VDABVNMGKGUPEY-UHFFFAOYSA-N 0.000 description 7
- 230000000890 antigenic effect Effects 0.000 description 7
- 230000007246 mechanism Effects 0.000 description 7
- 230000019491 signal transduction Effects 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 6
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 6
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 6
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 6
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 6
- 239000002671 adjuvant Substances 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- 239000013615 primer Substances 0.000 description 6
- 230000028327 secretion Effects 0.000 description 6
- 230000000638 stimulation Effects 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 5
- 101100005713 Homo sapiens CD4 gene Proteins 0.000 description 5
- 230000027455 binding Effects 0.000 description 5
- 230000004663 cell proliferation Effects 0.000 description 5
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 5
- 238000000684 flow cytometry Methods 0.000 description 5
- 230000005714 functional activity Effects 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 description 4
- 108010002586 Interleukin-7 Proteins 0.000 description 4
- 102000000704 Interleukin-7 Human genes 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 230000006044 T cell activation Effects 0.000 description 4
- 102100024324 Toll-like receptor 3 Human genes 0.000 description 4
- 230000000735 allogeneic effect Effects 0.000 description 4
- 230000003190 augmentative effect Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000004422 calculation algorithm Methods 0.000 description 4
- 238000002619 cancer immunotherapy Methods 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- 230000003308 immunostimulating effect Effects 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 230000000813 microbial effect Effects 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000001960 triggered effect Effects 0.000 description 4
- 108010029697 CD40 Ligand Proteins 0.000 description 3
- 102100032937 CD40 ligand Human genes 0.000 description 3
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 3
- 102000001398 Granzyme Human genes 0.000 description 3
- 108060005986 Granzyme Proteins 0.000 description 3
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 3
- 101000950669 Homo sapiens Mitogen-activated protein kinase 9 Proteins 0.000 description 3
- 101000669460 Homo sapiens Toll-like receptor 5 Proteins 0.000 description 3
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 3
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 3
- 108010055717 JNK Mitogen-Activated Protein Kinases Proteins 0.000 description 3
- 102000019145 JUN kinase activity proteins Human genes 0.000 description 3
- 239000000232 Lipid Bilayer Substances 0.000 description 3
- 102100037809 Mitogen-activated protein kinase 9 Human genes 0.000 description 3
- 102100039357 Toll-like receptor 5 Human genes 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 230000003127 anti-melanomic effect Effects 0.000 description 3
- 238000013528 artificial neural network Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000000539 dimer Substances 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 229930004094 glycosylphosphatidylinositol Natural products 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 238000009169 immunotherapy Methods 0.000 description 3
- 210000003071 memory t lymphocyte Anatomy 0.000 description 3
- 238000006384 oligomerization reaction Methods 0.000 description 3
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 3
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000010257 thawing Methods 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001052 transient effect Effects 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 102100026596 Bcl-2-like protein 1 Human genes 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 101710186200 CCAAT/enhancer-binding protein Proteins 0.000 description 2
- 108010009575 CD55 Antigens Proteins 0.000 description 2
- 210000001239 CD8-positive, alpha-beta cytotoxic T lymphocyte Anatomy 0.000 description 2
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 2
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 2
- 102000000844 Cell Surface Receptors Human genes 0.000 description 2
- 108010001857 Cell Surface Receptors Proteins 0.000 description 2
- 102100033295 Glial cell line-derived neurotrophic factor Human genes 0.000 description 2
- 101000599940 Homo sapiens Interferon gamma Proteins 0.000 description 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 2
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 102000004503 Perforin Human genes 0.000 description 2
- 108010056995 Perforin Proteins 0.000 description 2
- KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 2
- 108700012920 TNF Proteins 0.000 description 2
- 102100039390 Toll-like receptor 7 Human genes 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 2
- 108050002568 Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000001772 anti-angiogenic effect Effects 0.000 description 2
- 230000002424 anti-apoptotic effect Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 230000003305 autocrine Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 102000003675 cytokine receptors Human genes 0.000 description 2
- 108010057085 cytokine receptors Proteins 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 238000011580 nude mouse model Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 229930192851 perforin Natural products 0.000 description 2
- 230000002688 persistence Effects 0.000 description 2
- 229940115272 polyinosinic:polycytidylic acid Drugs 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000002987 primer (paints) Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000009877 rendering Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 108091006106 transcriptional activators Proteins 0.000 description 2
- 102000035160 transmembrane proteins Human genes 0.000 description 2
- 108091005703 transmembrane proteins Proteins 0.000 description 2
- 239000013638 trimer Substances 0.000 description 2
- 230000002476 tumorcidal effect Effects 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 1
- 108010063104 Apoptosis Regulatory Proteins Proteins 0.000 description 1
- 102000010565 Apoptosis Regulatory Proteins Human genes 0.000 description 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 108010001572 Basic-Leucine Zipper Transcription Factors Proteins 0.000 description 1
- 102000000806 Basic-Leucine Zipper Transcription Factors Human genes 0.000 description 1
- 108700031361 Brachyury Proteins 0.000 description 1
- 108010075254 C-Peptide Proteins 0.000 description 1
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 1
- 229940045513 CTLA4 antagonist Drugs 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 102100025680 Complement decay-accelerating factor Human genes 0.000 description 1
- 206010010264 Condition aggravated Diseases 0.000 description 1
- 102100023583 Cyclic AMP-dependent transcription factor ATF-6 alpha Human genes 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 208000001382 Experimental Melanoma Diseases 0.000 description 1
- 108010040721 Flagellin Proteins 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 101150066002 GFP gene Proteins 0.000 description 1
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 description 1
- 101000636168 Grapevine leafroll-associated virus 3 (isolate United States/NY1) Movement protein p5 Proteins 0.000 description 1
- WSDOHRLQDGAOGU-BQBZGAKWSA-N His-Asn Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CN=CN1 WSDOHRLQDGAOGU-BQBZGAKWSA-N 0.000 description 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
- 101000974934 Homo sapiens Cyclic AMP-dependent transcription factor ATF-2 Proteins 0.000 description 1
- 101000905751 Homo sapiens Cyclic AMP-dependent transcription factor ATF-6 alpha Proteins 0.000 description 1
- 101000997829 Homo sapiens Glial cell line-derived neurotrophic factor Proteins 0.000 description 1
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 description 1
- 101001028689 Homo sapiens Protein JTB Proteins 0.000 description 1
- 101100239730 Homo sapiens SLC8A1 gene Proteins 0.000 description 1
- 101100369992 Homo sapiens TNFSF10 gene Proteins 0.000 description 1
- 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 description 1
- 101000637726 Homo sapiens Toll/interleukin-1 receptor domain-containing adapter protein Proteins 0.000 description 1
- 101000962461 Homo sapiens Transcription factor Maf Proteins 0.000 description 1
- 108091054729 IRF family Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000016854 Interferon Regulatory Factors Human genes 0.000 description 1
- 102000013691 Interleukin-17 Human genes 0.000 description 1
- 108050003558 Interleukin-17 Proteins 0.000 description 1
- 102000003810 Interleukin-18 Human genes 0.000 description 1
- 108090000171 Interleukin-18 Proteins 0.000 description 1
- 102100030703 Interleukin-22 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010028921 Lipopeptides Proteins 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 102000016200 MART-1 Antigen Human genes 0.000 description 1
- 108010010995 MART-1 Antigen Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 1
- 101100369855 Mus musculus Tlr2 gene Proteins 0.000 description 1
- 102000010168 Myeloid Differentiation Factor 88 Human genes 0.000 description 1
- 108010077432 Myeloid Differentiation Factor 88 Proteins 0.000 description 1
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 description 1
- 239000012124 Opti-MEM Substances 0.000 description 1
- 102100037171 Protein JTB Human genes 0.000 description 1
- 101000613608 Rattus norvegicus Monocyte to macrophage differentiation factor Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 102100035088 Sodium/calcium exchanger 1 Human genes 0.000 description 1
- 230000020385 T cell costimulation Effects 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 230000037453 T cell priming Effects 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 108700012411 TNFSF10 Proteins 0.000 description 1
- 108010017842 Telomerase Proteins 0.000 description 1
- 210000004241 Th2 cell Anatomy 0.000 description 1
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 description 1
- 102100033117 Toll-like receptor 9 Human genes 0.000 description 1
- 102100032120 Toll/interleukin-1 receptor domain-containing adapter protein Human genes 0.000 description 1
- 102100039189 Transcription factor Maf Human genes 0.000 description 1
- 102100024598 Tumor necrosis factor ligand superfamily member 10 Human genes 0.000 description 1
- 235000009499 Vanilla fragrans Nutrition 0.000 description 1
- 244000263375 Vanilla tahitensis Species 0.000 description 1
- 235000012036 Vanilla tahitensis Nutrition 0.000 description 1
- 230000004721 adaptive immunity Effects 0.000 description 1
- 102000035181 adaptor proteins Human genes 0.000 description 1
- 108091005764 adaptor proteins Proteins 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000000919 anti-host Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000006023 anti-tumor response Effects 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000011748 cell maturation Effects 0.000 description 1
- 230000010307 cell transformation Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 108700010039 chimeric receptor Proteins 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 230000006552 constitutive activation Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 230000000368 destabilizing effect Effects 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000009088 enzymatic function Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 102000045718 human TLR2 Human genes 0.000 description 1
- 210000005104 human peripheral blood lymphocyte Anatomy 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 239000000568 immunological adjuvant Substances 0.000 description 1
- 230000006054 immunological memory Effects 0.000 description 1
- 210000005008 immunosuppressive cell Anatomy 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 108040006849 interleukin-2 receptor activity proteins Proteins 0.000 description 1
- 108010074108 interleukin-21 Proteins 0.000 description 1
- 238000010212 intracellular staining Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 108020001756 ligand binding domains Proteins 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000011469 lymphodepleting chemotherapy Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 208000021039 metastatic melanoma Diseases 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 238000007826 nucleic acid assay Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 238000003909 pattern recognition Methods 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 230000008672 reprogramming Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108091008023 transcriptional regulators Proteins 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000004222 uncontrolled growth Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464416—Receptors for cytokines
- A61K39/464417—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5434—IL-12
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5443—IL-15
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/57—Skin; melanoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C07K2319/41—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C07K2319/42—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a HA(hemagglutinin)-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
Definitions
- the present invention relates in general to central nervous system (CNS) injuries and, in particular, to sub-populations of human monocytes useful in the treatment of CNS injuries, methods for isolation of these sub-populations and treatment of patients suffering from spinal cord injury.
- CNS central nervous system
- the present invention relates to the field of adoptive cell therapy and the use of activated T cells expressing constitutively active (ca) CD40 molecules, caTLR4 molecules, membrane-bound cytokines and combinations thereof.
- adoptive cell therapy involves the administration of large numbers of highly selective cells with high avidity for tumor antigens.
- T cells can be programmed and activated ex vivo to exhibit antitumor effector functions.
- T cell infusion may be preceded by 'conditioning' of the patient with lymphodepleting chemotherapy or total body irradiation, which enables the diminution of immunosuppressive cell types/factors followed by the infusion of tumor-specific T cells.
- TILs tumor-infiltrating lymphocytes
- APCs artificial antigen-presenting cells
- beads coated with T cell ligands and activating antibodies or cells isolated by virtue of capturing target cell membrane
- allogeneic cells naturally expressing anti-host tumor T cell receptor (TCR)
- non-tumor-specific autologous or allogeneic cells genetically reprogrammed or "redirected" to express tumor-reactive TCR or chimeric TCR molecules displaying antibody-like tumor recognition capacity known as "T-bodies”.
- ACT is currently the most effective treatment for patients with metastatic melanoma, and is extensively explored for the treatment of other human cancers.
- major obstacles which limit the clinical benefit and broader application of this approach.
- some of the intrinsic difficulties are attributable to the particular method employed for isolation, propagation or generation of the effector lymphocytes, others, such as the exhaustion of the proliferative and survival potential of fully differentiated T cells, seem to be a more general phenomena related to the effector phenotype.
- Thl- promoting cytokines such as interleukin (lL)-2, IL-12 and IL-15
- cytokines such as interleukin (lL)-2, IL-12 and IL-15
- CTLA-4 or PD-1 contact- dependent T cell suppression by CTLA-4 or PD-1
- depletion or attenuation of Tregs blockade of TGF- ⁇
- costimulatory signaling pathways such as CD28, 4- IBB and OX40
- introduction of anti-apoptotic genes e.g. Bcl-2, Bcl-xL
- TLR agonists e.g. Bcl-2, Bcl-xL
- the present invention relates, in one aspect, to polynucleotides comprising a sequence encoding a chimeric protein comprising a cytoplasmic domain of a T cell costimulatory receptor of the tumor necrosis factor receptor (TNFR) family that is linked to a heterologous polypeptide comprising at least one self-assembly domain, said chimeric peptide being linked to an integral membrane or a transmembrane oligopeptide that allows the anchorage of the chimeric polypeptide to the cell membrane.
- TNFR tumor necrosis factor receptor
- the invention relates to polynucleotides comprising a sequence encoding a chimeric protein comprising a cytoplasmic constitutively active domain of a TLR4 molecule linked through its amino terminus to an integral membrane or transmembrane oligopeptide that allows the anchorage of the TLR4 molecule to the cell membrane, and said transmembrane oligopeptide, if existent, is linked, optionally via a bridge peptide, to a peptide tag or oligopeptide tag.
- the invention relates to polynucleotides comprising a sequence encoding a chimeric protein comprising a cytokine linked through its carboxyl terminus via a flexible bridge peptide to an integral membrane or transmembrane oligopeptide that allows the anchorage of the cytokine molecule to a cell membrane, with the proviso that said chimeric protein does not comprise IL-2 linked to a glycoinositol phospholipid, IL-12 linked to the costimulatory molecule CD80 (B7.1) or IL-15 linked to IL-15 RA.
- the polynucleotide encoding a chimeric protein comprising a cytoplasmic domain of a T cell costimulatory receptor of the TNFR family or the chimeric protein comprising a cytoplasmic constitutively active domain of a TLR4 is each linked to an integral membrane or a transmembrane oligopeptide that allows the anchorage of the chimeric polypeptide to the cell membrane, wherein said transmembrane oligopeptide is linked via a flexible bridge peptide to the carboxyl terminus of a cytokine.
- the present invention relates to expressions vectors and compositions comprising the above-identified polynucleotides or any combination thereof, and to activated T cells expressing at least one chimeric protein encoded by these polynucleotides.
- the present invention relates to methods for treating cancer, comprising administering to a cancer patient a therapeutically effective amount of activated tumor specific T cells expressing the chimeric proteins of the present invention; and to methods for preparing activated T cells comprising transfecting said T cells with a polynucleotides or expression vectors as defined herein, whereby the polynucleotide is expressed within said T cells, thus obtaining the activated T cells.
- the present invention provides a method for propagating T cells, comprising transfecting said T cells with a polynucleotide comprising a sequence encoding a chimeric protein comprising IL-2 linked through its carboxyl terminus via a flexible bridge peptide to an integral membrane or transmembrane oligopeptide that allows the anchorage of the IL-2 molecule to a cell membrane.
- Fig. 1 depicts flow cytometry analysis showing expression of GFP in human CD8 T cells following mRNA transfection. Fluorescence was analyzed 24 hours after transfection against the same cells undergoing an identical treatment but receiving no RNA (filled black histogram). Ml, Marker 1 : the range used to calculate specific, relative to total, fluorescence and MFI (mean fluorescence intensity).
- Figs. 2A-B depict schemes of the basic genetic construct (A) and the resulting MHC-I molecules at the cell surface (B).
- FIG. 3 shows a bar graph demonstrating that human peripheral blood lymphocyte (PBL)-derived CD4 and CDS T cells produce interferon-7 (IFN- ⁇ ) following transfection with 5 /ig caTLR4- (but not caTLR2- or EGFP-) encoding mRNA.
- PBL peripheral blood lymphocyte
- CDS T cells produce interferon-7 (IFN- ⁇ ) following transfection with 5 /ig caTLR4- (but not caTLR2- or EGFP-) encoding mRNA.
- NT non- treated
- LPS lipopolysaccharide
- Pam3, Pam3CysS 4 is a bar graph demonstrating that human peripheral blood lymphocyte (PBL)-derived CD4 and CDS T cells produce interferon-7 (IFN- ⁇ ) following transfection with 5 /ig caTLR4- (but not caTLR2- or EGFP-) encoding mRNA.
- NT non- treated
- LPS lipopolysaccharide
- FIGs. 4A-B demonstrates that as little as 1 ⁇ g caTLR4 mRNA activates human CD4 (A) and CD8 (B) T cells derived from PBLs of healthy HLA-A2+ (A2+) and HLA- A2- (A2-) donors.
- Transfection of either peptide-p2m-TLR4 (construct 500) or 2m-TLR4 only (construct 931) were performed with 1 or 5 /xg in-vitro-transcribed mRNA.
- Non- treated cells or cells similarly transfected with EGFP-encoding mRNA (GFP) served as a negative control, and cells transfected with EGFP mRNA and treated with LPS (1 ⁇ g ml) served as a reference.
- GFP EGFP-encoding mRNA
- Figs. 5A-B show a flow cytometry analysis for the expression of CD25 by the tumor specific CTL clone, 1C9, (A) and the expression of CD69 by the primary TIL 431-4 (B), following transfection of 5 ⁇ g mRNA encoding either 2m-HLA-A2 (construct 541), caTLR4 (construct 931) or GFP (construct 540; irrelevant RNA). GFP served as an indicator for transfection efficiency (upper panel).
- N G2D an activating receptor that is expressed by T cells, as well as by natural killer ( ) cells and macrophages; CD 137, a lymphocyte activation marker also known as 4- IBB.
- Figs. 6A-C depict the design of oligomeric derivatives of hCD40.
- A The basic scheme of the genetic construct.
- B The expected organization of the GCN4 coiled coil motifs.
- C The expected oligomerization of the encoded polypeptides.
- Fig. 7 depicts a scheme of the chimeric gene encoding for single chain IL-12. Pr, Promoter; Spe I, Xma I, Xho I and Not I, restriction sites.
- Fig. 8 shows CFSE dilution assay for cell proliferation.
- CD8 T cells were prepared from PBLs of a healthy donor, grown for 4 days in OKT3 and IL-2 and separated to CD8 and CD4 T cells. Following 24 h rest were transfected or treated as indicated. Results are presented as % of live cells with decreased CFSE staining relative to the initial histogram.
- Fig. 9 shows that here is functional synergy between genetic adjuvants.
- Melanoma TILs grown the presence of 2,000 U/ml IL-2 for 4 days, were electroporated with 10 ⁇ g each mRNA. 24 hours post-transfection growth medium was collected for IFN- ⁇ ELISA. No, non-treated cells; N.R., irrelevant mRNA. GFP mRNA served as an additional negative control and as a reference for transfection yield.
- Figs. 10A-B show restoration of TIL-425 functional activity by the genetic adjuvants.
- Anti-melanoma CD8 TILs were transfected with mRNA encoding caCD40, memIL3 ⁇ 4 caTLR4, their indicated combinations and an irrelevant mRNA as a negative control. 3 days post transfection the cells were incubated with relevant M427 melanoma (A) or irrelevant M171 melanoma (B). Flow cytometry analysis for IFN- ⁇ (intracellular staining, upper panels) and cytolysis-associated degranulation (CD107, lower panels).
- adoptive cell therapy is one of the most promising approaches being developed for treating cancer.
- ACT adoptive cell therapy
- a network of suppressive mechanisms operating at the tumor site, T cell exhaustion, down regulated effector mechanisms and low persistence of the transferred cells are critical factors which limit clinical efficacy and broader use of ACT.
- the present invention is based on a novel genetic approach designed to overcome these complications and maximize the curative potential of tumor-reactive T cells in ACT.
- the central components of this approach are based on the concept of severing T cell activation from the ligand-dependent activation of T cell activating factors by expressing in the T cells constitutively active factors; and on the concept of confining the activity of T cell promoting cytokines, which are naturally secreted from the cells, preventing their undesired consumption by competing cells (mainly Tregs) and coupling their activity to that of other T cell activating factors, by expressing these cytokines in T cells as integral membranal proteins.
- T cells T cells
- TNFR tumor necrosis factor receptor
- the present invention is thus directed to a polynucleotide comprising a sequence encoding a chimeric protein comprising a cytoplasmic domain of a T cell costimulatory receptor of the tumor necrosis factor receptor (TNFR) family that is linked to a heterologous polypeptide comprising at least one self-assembly domain, said chimeric peptide being linked to an integral membrane or a transmembrane oligopeptide that allows the anchorage of the chimeric polypeptide to the cell membrane.
- TNFR tumor necrosis factor receptor
- polypeptide encoded by the polynucleotides defined above is termed herein "self- aggregating TNFR polypeptide", for example as in “self-aggregating CD40", “constitutively active T cell costimulatory receptor of the TNFR family” or "caTNFR”.
- the candidates in this family that are most relevant to the present invention are CD40, CD27, 4-1BB (CD137), OX40 (CD134), herpesvirus entry mediator (HVEM; also known as TNFRSF14), CD30 and glucocorticoid-induced TNFR-related protein (GITR).
- HVEM herpesvirus entry mediator
- TNFRSF14 glucocorticoid-induced TNFR-related protein
- GITR glucocorticoid-induced TNFR-related protein
- 4-1BB is expressed on activated human T cells. Its ligation by cognate ligand expressed on the surface of antigen-presenting cells (APCs) or by antibodies or soluble ligand promotes T cell survival by upregulating anti-apoptotic genes, induces cell division, augments Thl cytokine production, protects T cells from antigen-induced cell death, induces memory formation and confers resistance to Treg suppression. Results from different experimental systems have described the beneficial anti-tumor effect of 4-1 BB stimulation in- vivo.
- APCs antigen-presenting cells
- soluble ligand promotes T cell survival by upregulating anti-apoptotic genes, induces cell division, augments Thl cytokine production, protects T cells from antigen-induced cell death, induces memory formation and confers resistance to Treg suppression.
- OX40 is a late costimulatory receptor expressed on activated CD4 and CD8 T cells. OX40 ligation promotes T cells survival, proliferation, migration to sites of inflammation, memory formation and abrogation of suppression. Similarly to 4- IBB, a large body of evidence maintains that OX40 stimulation augments anti-tumor T cell reactivity.
- CD40 is also expressed on both CD8 and CD4 T cells, playing an intrinsic role in T cell costimulation, memory formation, rescue from exhaustion and contra-Treg activity.
- the T cell costimulatory receptor of the T FR family is selected from CD40, CD27, 4- IBB (CD137), OX40 (CD 134), HVEM, CD30 or GITR, preferably the human homolog of these receptors.
- TNFR-associated factor (TRAF) proteins via the NF-/3B, p38 MAPK or JNK/SAPK pathways.
- Signaling entails receptor homo-oligomerization, which is induced by engagement with their respective homo- oligomeric (typically homotrimeric) ligands.
- a skilled artisan may easily assess if a cell expresses a molecule that has ligand-independent characteristic TNFR activity as measured for example by the activation of downstream signal pathways as recited above.
- the self-assembly domain that mediates the aggregation of the chimeric protein comprising the full or partial intracellular domain of a TNFR molecule may be any such self-assembly domain known in the art, such as a coiled-coil domain.
- coiled coils comprise two or more a-helices that supercoil around each other to form rope-like structures.
- these motifs usually have a repeating pattern of seven residues called the heptad repeat, and often designated abcdefg. Residues at a and d positions are predominantly hydrophobic, which results in a hydrophobic stripe along each participating helix.
- a coiled-coil is the leucine zipper motifs present in many DNA-binding proteins transcriptional regulators, some of which are listed in Miller (2009), incorporated herein by reference.
- leucine zipper is that of the C/EBP a basic region: leucine zipper (bZIP) protein of the amino acid sequence of SEQ ID NO: 1 ; each seven amino acid residues of which forms a heptad.
- Non-limiting examples of human bZIP protein families mentioned in the Miller paper are C/EBP a, AP-1 (including the Jun subfamily, Fos subfamily and ATF2&4 subfamily), C EB/ATF, ATF6, PAR, MAF and CNC families.
- C/EBP a C/EBP a
- AP-1 including the Jun subfamily, Fos subfamily and ATF2&4 subfamily
- C EB/ATF C EB/ATF
- ATF6, PAR MAF and CNC families.
- the self-assembly domain of each of these proteins, but not limited to them, is contemplated by the present invention for use in the chimeric polypeptide of the present invention.
- association domains tetramerization domains of the vanilla receptor as taught by Garci'a-Sanz et al. (2004).
- the coiled-coil domain may be a yeast GCN4 leucine zipper DNA-binding motif, which depending on its particular amino acid sequence, is capable of forming homodimers, homotrimers, or homotetramers.
- a CD40 genetic construct as a template, and incorporated the GCN4 binding motifs in 3 configurations encoding dimers, trimers and tetramers, based on Harbury et al, (1993; 1995).
- the self-assembly domain is a yeast GCN4 leucine zipper DNA-binding motif, in particular the yeast GCN4 leucine zipper DNA- binding motif of SEQ ID NO: 2 forming homodimers, SEQ ID NO: 3 forming homotrimers or SEQ ID NO: 4 forming homotetramers.
- the self-aggregating TNFR polypeptide could conceivably be anchored by any transmembrane oligopeptide known in the art (see below).
- the cytoplasmic constitutively active domain of the TNFR molecule of the chimeric protein of the present invention is linked to an integral membrane or transmembrane oligopeptide that allows the anchorage of the TNFR molecule to a cell membrane.
- the TNFR moiety may be linked to an oligopeptide which is buried in the lipid bilayer and does not protrude to the other side of the membrane.
- the transmembrane oligopeptide of the TNFR chimeric protein is the transmembrane oligopeptide of CD40.
- the term “contralateral” is used herein to describe the side of the membrane which is opposite to the side of the constitutively active TNFR signal conducting moiety.
- the contralateral side is the extracellular side.
- the term “contralateral protein” is used herein to describe a protein or peptide attached to the transmembrane stretch on the contralateral side of the membrane.
- the contralateral protein is a peptide tag or oligopeptide tag.
- the contralateral protein to which the transmembrane stretch may be attached via the bridge peptide is not essential for the proper activation of the T cells by the TNFR molecule and could thus be chosen according to its desired function such as, but not limited to, detection or purification of the expressed protein (e.g. a His-tag (e.g. His 6 ), a (His-Asn) tag, a Flag tag, a Ha tag, a fluorescent protein, such as enhanced green fluorescent protein (EGFP), or any other tag that may facilitate the purification and identification of the chimeric protein), or an enzymatic function.
- peptide, oligopeptide and peptide-tag as used herein are defined as a peptide or oligopeptide that has no functional activity and that can be detected with a specific detecting agent, such as a specific antibody.
- a specific detecting agent such as a specific antibody.
- the tag may be His 6 .
- the transmembrane oligopeptide of the TNFR chimeric protein oligopeptide is linked, optionally via a bridge peptide comprises an amino acid stretch of about 5 amino acids to about 15 amino acids, preferably 13 amino acids of the membrane-proximal amino acids of human HLA-A2, to a peptide tag.
- the peptide tag may be selected from, but is not limited to, Ha tag, a His tag or a Myc tag.
- CD40 constitutively active, ligand-independent CD40, which confers a constitutively activated state on transfected T cells, by linking CD40 to the GCN4 yeast transcriptional activator, which contains a leucine zipper DNA-binding motif that induces homophilic interactions, and thus induces self-oligomerizing.
- TNFR members mentioned here bear structural similarities and they all signal through adaptor TNFR-associated factor (TRAF) proteins via the NF-0B, p38 MAP or JNK/SAPK pathways, one may assume that also the other TNFR members, when linked to a self-assembly domain, will become constitutively active, that are capable of conferring a constitutively activated state on transfected T cells.
- TNF TNFR-associated factor
- self- ggregating TNFR polypeptide or “constitutively active T cell costimulatory receptor of the TNFR family” as used herein thus refer to any polypeptide with minor variations in its amino acid sequence as compared with the self- aggregating TNFR polypeptides defined herein, that have ligand-independent characteristic TNFR activity as measured for example by the activation of downstream signal pathway elements such - NF-jSB, p38 MAPK or JNK/SAPK.
- the polynucleotide encoding the constitutively active T cell costimulatory receptor of the TNFR family comprises the following nucleotide sequences: (a) the sequence of SEQ ID NO: 5 encoding for the leader peptide of the human /32m gene; (b) a sequence encoding for a peptide tag for detection selected from: (i) Ha tag of SEQ ID NO: 6; (ii) Myc tag of SEQ ID NO: 7; or (iii) His tag of SEQ ID NO: 8; (c) the sequence of SEQ ID NO: 9 encoding a bridge peptide; (d) the sequence of SEQ ID NO: 10 encoding for the transmembrane domain of human CD40; (e) the sequence of SEQ ID NO: 11 encoding for a GCN4-derived homo-oligomerizing domain forming homotrimers; and (f) a sequence encoding for the cytosolic signaling domain of a T cell cost
- nucleic acid sequences i.e. polynucleotides
- polypeptide encoded by the first nucleic acid has activity that is identical to, or characteristic of, the polypeptide encoded by the second nucleic acid.
- a polypeptide is typically substantially identical to a second polypeptide, for example, where the two peptides differ only by conservative substitutions.
- Another indication that two nucleic acid sequences are substantially identical is that the two molecules or their complements hybridize to each other under stringent conditions, as described below.
- Yet another indication that two nucleic acid sequences are substantially identical is that the same primers can be used to amplify the sequence.
- stringent hybridization conditions refers to conditions under which a probe will hybridize to its target subsequence, typically in a complex mixture of nucleic acids, but to no other sequences. Stringent conditions are sequence-dependent and will be different in different circumstances. Longer sequences hybridize specifically at higher temperatures. An extensive guide to the hybridization of nucleic acids is found in Tijssen, Techniques in Biochemistry and Molecular Biology— Hybridization with Nucleic Probes , “Overview of principles of hybridization and the strategy of nucleic acid assays” (1993). Generally, stringent conditions are selected to be about 5-10° C lower than the thermal melting point (Tm) for the specific sequence at a defined ionic strength pH.
- Tm thermal melting point
- the Tm is the temperature (under defined ionic strength, pH, and nucleic concentration) at which 50% of the probes complementary to the target hybridize to the target sequence at equilibrium (as the target sequences are present in excess, at Tm , 50% of the probes are occupied at equilibrium).
- Stringent conditions may also be achieved with the addition of destabilizing agents such as formamide.
- a positive signal is at least two times background, preferably 10 times background hybridization.
- Exemplary stringent hybridization conditions can be as following: 50% formamide, 5xSSC, and 1% SDS, incubating at 42° C, or, 5xSSC, 1% SDS, incubating at 65° C, with wash in 0.2xSSC, and 0.1% SDS at 65° C.
- nucleic acids that do not hybridize to each other under stringent conditions are still substantially identical if the polypeptides which they encode are substantially identical. This occurs, for example, when a copy of a nucleic acid is created using the maximum codon degeneracy permitted by the genetic code. In such cases, the nucleic acids typically hybridize under moderately stringent hybridization conditions.
- Exemplary "moderately stringent hybridization conditions” include a hybridization in a buffer of 40% formamide, 1 M NaCl, 1% SDS at 37° C, and a wash in l SSC at 45° C. A positive hybridization is at least twice background.
- Those of ordinary skill will readily recognize that alternative hybridization and wash conditions can be utilized to provide conditions of similar stringency. Additional guidelines for determining hybridization parameters are provided in numerous reference, e.g., Current Protocols in Molecular Biology , ed. Ausubel, et al.
- the nucleic acid sequences are at least about 80%, 90%, 95%, or 97-98%, or 100% identical to the sequences of SEQ ID NOs: 5-20 and 23- 29, respectively, as assessed using a computer program such as BLAST (available at the National Center for Biotechnology Information, USA) that finds regions of similarity between biological sequences.
- BLAST available at the National Center for Biotechnology Information, USA
- the polynucleotide encoding the constitutively active T cell costimulatory receptor of the TNFR family comprises the sequence of (iv) encoding for the cytosolic signaling domain of CD40.
- T cells refers to T-lymphocytes taken directly from a living mammal; they do not include in their scope immortalized T cell lines, such as Jurkat cells.
- TLR2 engagement on these cells triggers interferon (IFN)-Y production, lowers the activation threshold, enhances cell proliferation and survival, maintains T cell memory, attenuates regulatory T cell (Treg)-mediated suppression and renders effector T cells resistant to this suppression.
- IFN interferon
- DCs Dendritic cells
- APCs antigen presenting cells
- TLRs TLRs
- the particular TLRs engaged by these cells in the periphery polarize the ensuing response towards the Thl, Th2, Thl7 or the Treg course, and the elucidation in recent years of the functional consequences of TLR engagement on particular cell subsets is harnessed in vaccine development.
- Cumulative findings ascribe a critical role for Tregs in the suppression of tumor-reactive T cells. Treg activity can be modulated by agonists of TLR2, TLR5 and TLRS, and these can be exploited in cancer immunotherapy.
- TLR2 which appears to be a key TLR family member that can directly stimulate T cell survival and proliferation and boost effector functions.
- TLR2 which appears to be a key TLR family member that can directly stimulate T cell survival and proliferation and boost effector functions.
- BLP bacterial lipopeptide
- CD4+ CD45RO+ memory T cells constitutively expressed TLR2 produced IFN- ⁇ and manifested elevated proliferative capacity in response to BLP.
- Cottalorda et al. (2006) showed that BLP stimulation of mouse CD 8 T cells led to increased cell proliferation and survival, and these were associated with a sustained expression of IL-2 receptor ct-chain (IL-2Ro: or CD25) and enhanced expression of the anti-apoptotic protein Bcl-xL.
- IL-2Ro IL-2 receptor ct-chain
- BLP upregulated IFN- ⁇ and granzyme B secretion augmented the overall cytotoxic activity of antigen- activated T cells and lowered the threshold of their initial activation by APCs.
- TLR2 triggered by 2 different ligands
- IFN-7 IFN-7 production
- cell proliferation and cell survival in mouse Thl cells
- TLR2 ligands induced IFN- ⁇ also by CD8 T cells pre-stimulated with anti-TCR and CD28 Abs.
- Asprodites et al. (2008) showed that BLP augmented the anti-melanoma activity of TLR2-proficient, but not deficient, CD8 T cells from the TCR transgenic OT-1 mice.
- TLR3 was shown to be expressed by human effector CD8 T cells (Tabiasco et al, 2006).
- the bacterial TLR3 agonist poly(I:C) increased IFN- ⁇ secretion induced by TCR-dependent and -independent stimulation of these cells, but without affecting proliferation or specific cytolytic activity.
- TLRs Removal of the ligand-binding domain of most, if not all, TLRs results in constitutive signaling triggered by the truncated derivatives, referred to as constitutively active (ca), or dominant positive (DP) TLRs.
- TLR ligands of microbial origin as immunological adjuvants to directly augment T cell effector functions either in- vivo or ex-vivo is intriguing; however, this may produce undesirable side effects and is not favored from a regulatory point of view.
- the inventors have also utilized the genetic platform for targeting antigenic peptides to MHC-I presentation in antigen presenting cells.
- the selected antigenic peptides are fused to the N-terminus of /32m which is anchored to the membrane as described above.
- WO 01/091698 teaches antigenic peptides related to an autoimmune disease and WO 03/106616, of the same applicants, teaches antigenic peptides not related to an autoimmune disease, i.e. the antigenic peptide is derived from a tumor associated, bacterial, viral, fungal or parasite antigen.
- US 2008/0286312 and WO 08/041231 teaches a construct encoding /32m anchored to the membrane by the means of the intracellular and transmembrane regions of TLR4, which confers activation of antigen presenting cells expressing the construct.
- WO01091698, WO 03/106616, US 2008/0286312 and WO 08/041231 are all hereby incorporated by reference in their entirety as if fully disclosed.
- TLR4 is known in the art to be expressed in T cells as described above.
- expression of constitutively active (transmembranal and cytosolic domains) (caTLR4) caTLR4 mRNA transfected T cells causes extraordinary activation of both CD4 and CD8 T cells.
- TLR4 is not believed to be functionally expressed in T cells as evidenced by the absence of a response of T celjs exposed to TLR4 ligands such as LPS as described above.
- TLR4 is capable of activating Jurkat cells (Medzhitov et al, 1997), has always been considered in the art to be a specific feature of this immortalized cell line, and not as a feature shared by T cells due to the latter' s refractoriness to LPS, and has not prompted researchers to attempt expressing TLR4 in T cells.
- TLR2 and TLR4 signaling pathways differ, T cells in general would not be expected to possess all the downstream components required for TLR4 signaling.
- TLR2- mediated signaling is solely transduced through the recruitment of the MyD88 and TIRAP adaptor proteins, which leads to the activation of the transcription factors NF- ⁇ and AP- 1.
- TLR4 also harnesses the TRIF-TRAM set of adaptors, a pathway which culminates in the activation of interferon regulatory factors.
- the T cells activated by these two constitutively active molecules may thus be transfected with a single polynucleotide or vector encoding for both molecules, or it may be transfected with two separate molecules, e.g. RNA molecules, each one encoding for one of the two molecules.
- the present invention provides a polynucleotide comprising a sequence encoding a chimeric protein comprising a cytoplasmic constitutively active domain of a TLR4 molecule linked through its amino terminus to an integral membrane or transmembrane oligopeptide that allows the anchorage of the TLR4 molecule to the cell membrane, and said transmembrane oligopeptide, if existent, is linked, optionally via a bridge peptide, to a peptide tag or oligopeptide tag.
- the polynucleotide encoding the constitutively active T cell costimulatory receptor of the TNFR family comprises a further sequence encoding a chimeric protein comprising a cytoplasmic constitutively active domain of a TLR4 molecule linked through its amino tenninus to an integral membrane or transmembrane oligopeptide that allows the anchorage of the TLR4 molecule to the cell membrane, and said transmembrane oligopeptide, if existent, is linked, optionally via a bridge peptide, to a peptide tag or oligopeptide tag.
- caTLR4 refers to any polypeptide with minor variations in its amino acid sequence as compared with transmembranal and cytosolic domains of human TLR4 (based on the sequence as set forth at GBA NM138554), that have ligand-independent characteristic TLR4 activity as measured for example by the activation of downstream signal pathway elements such myD88, TRIF-TRAM or NFKB.
- the cytoplasmic constitutively active domain of the TLR4 molecule could conceivably be anchored by any transmembrane oligopeptide known in the art (see below).
- the cytoplasmic constitutively active domain of the TLR4 molecule of the chimeric protein of the present invention is linked through its amino terminus to an integral membrane or transmembrane oligopeptide that allows the anchorage of the TLR4 molecule to a cell membrane.
- the TLR4 moiety may be linked to an oligopeptide which is buried in the lipid bilayer and does not protrude to the other side of the membrane.
- the TLR4 moiety is preferably anchored to a cell membrane by its ow native transmembrane oligopeptide.
- the TLR4 is a human TLR4.
- the bridge peptide (which is linked to the TLR4 transmembrane oligopeptide) comprises an amino acid stretch of about 5 amino acids to about 15 amino acids, preferably 13 amino acids of the membrane-proximal amino acids of human HLA-A2.
- the peptide tag is selected from, but is not limited to, Ha tag, a His tag or a Myc tag.
- the polynucleotide encoding for the caTLR4 may comprise the following nucleotide sequences: (a) the sequence SEQ ID NO: 17 encoding for the 5' non- translated region of ⁇ 2 ⁇ ; (b) the sequence SEQ ID NO: 18 encoding for the human ⁇ 2 ⁇ leader peptide; (c) a sequence encoding for a peptide tag for detection selected from: (i) Ha tag of SEQ ID NO: 6; (ii) Myc tag of SEQ ID NO: 7; or (iii) His tag of SEQ ID NO: 8; (d) the sequence of SEQ ID NO: 9 encoding a bridge peptide; (e) the sequence SEQ ID NO: 19 encoding for human transmembrane and cytosolic domains of TLR4; and (f) the sequence
- Thl immunostimulatory cytokines are IL-la, IL-2, IL-7, IL-12, IL-15, IL-17, IL-18, IL-21, TNF- ⁇ 3 ⁇ 4 IFN-o IFN-0 and IFN- ⁇ .
- IL-2 is an essential factor for the growth, differentiation and survival of antigen-selected T cells. It is a 15.5 kDa protein comprising a single polypeptide chain of 133 amino acids. IL-2 is naturally produced by activated T cells and functions in an autocrine or paracrine manner. It binds to a heterotrimeric high affinity receptor comprising IL-2Ra (CD25), IL-2/15R/3 and the common cytokine-receptor ⁇ -chain (7c). IL-2 is evidently the most widely explored cytokine in cancer immunotherapy and particularly in ACT.
- IL-2 substantially augments the TLR-2-mediated enhancement of the functional and proliferative status of T cells.
- IL-12 is a Thl polarizing cytokine, driving the differentiation of CD4 Thl and CD8 T cells and natural killer (NK) cells and is also known. for its anti-angiogenic activity. It stimulates IFN- ⁇ and TNF-a production from T and NK cells.
- IL-12 is a heterodimeric cytokine, consisting of two gene products: p35 and p40. It is produced mainly by activated DCs and binds to its heterodimeric receptor comprising IL-12R-/31 and IL-12R-
- the anti-rumor activities of IL-12 have been explored in cancer immunotherapy, gene therapy and ACT .
- IL-12 was capable of amplifying the observed influence of TLR2 ligands on T cell effector functions.
- the production of different forms of recombinant IL-12 or its gene delivery were facilitated by the development of single-chain derivatives of this cytokine, which retain the functional properties of the native protein (Chakrabarti et al (2004), Lode et al (1998), Lee et al, 1998).
- IL-15 is a T cell (and NK cell) stimulating cytokine. It induces the generation of primary and memory antigen-specific CD8. T cells, mediates CD4 T cell help to promote longevity of CD8 cells and prevent their TRAIL-induced apoptosis. In particular, IL-15 induces telomerase activity in CD8 T cells and prolongs their proliferation. IL-15 synergizes with TLR2 in promoting proliferation of, and IFN-7 production by, human CD4 T cells. IL-15 is a key cytokine used in ACT in ex- vivo generation, and propagation of tumor-reactive effector T cells.
- T cells engineered to express IL-15 exhibited improved anti-rumor activity and prolonged survival in- vivo (Quintarelli et al (2007), Hsu et al (2005), Klebanoff et al., 2004). It has been shown that in addition to IL-2 consumption, Tregs can bind and eliminate IL-15 (and IL-4 and IL-7).
- IL-2 As an integral membranal constituent of transfected cells, the inventors have genetically engineered IL-2 as an integral membranal constituent of transfected cells.
- Membranal (mem) IL-2 was designed with a flexible spacer so as to engage its cell surface receptor in-cis (that is, on the same cell). As long as both the gene product and its endogenous IL-2 receptor are expressed at the cell surface this closed system is expected to signal constitutively, precluding IL-2 intake by tumor-resident Tregs and other cells and avoiding systemic dissemination and subsequent side effects.
- the T cells activated by these two molecules may thus be transfected with a single polynucleotide or vector encoding for both molecules, or it may be transfected with two separate molecules, e.g. RNA molecules, each one encoding for one of the two molecules.
- the T cells may be transfected with a single polynucleotide encoding a cytokine, grafted via a bridge peptide and a transmembrane oligopeptide, to the cytoplasmic domain of the self-aggregating TNFR polypeptide of the present invention, or the cytoplasmic domain of the caTLR4 of the present invention.
- the polynucleotide of the present invention encodes for the constitutively active T cell costimulatory receptor of the TNFR family, or the constitutively active TLR4, wherein the constitutively active T cell costimulatory receptor of the TNFR family, or the constitutively active TLR4, is linked through a transmembrane oligopeptide via a flexible bridge peptide to the carboxyl terminus of a cytokine.
- the polynucleotide of the present invention may also encode for a chimeric protein comprising a cytoplasmic domain of a T cell costimulatory receptor of the tumor necrosis factor receptor (TNFR) family that is linked to a heterologous polypeptide comprising at least one self-assembly domain, said chimeric peptide being linked to an integral membrane or a transmembrane oligopeptide that allows the anchorage of the chimeric polypeptide to the cell membrane, and a chimeric protein comprising a cytokine linked through its carboxyl terminus via a flexible bridge peptide to a cytoplasmic constitutively active domain of a TLR4 molecule.
- TNFR tumor necrosis factor receptor
- the polynucleotide of the present invention may encode for a chimeric protein comprising a cytoplasmic constitutively active domain of a TLR4 molecule linked through its amino terminus to an integral membrane or transmembrane oligopeptide that allows the anchorage of the TLR4 molecule to the cell membrane, and said transmembrane oligopeptide, if existent, is linked, optionally via a bridge peptide, to a peptide tag or oligopeptide tag, and a chimeric protein comprising a cytokine linked through its carboxyl terminus via a flexible bridge peptide to a self-aggregating cytoplasmic domain of a T cell costimulatory receptor of the tumor necrosis factor receptor (TNFR) family.
- TNFR tumor necrosis factor receptor
- the polynucleotide of the present invention encoding for the constitutively active T cell costimulatory receptor of the TNFR family, or the constitutively active TLR4 comprises a further sequence encoding a chimeric protein comprising a cytokine linked through its carboxyl terminus via a flexible bridge peptide to an integral membrane or transmembrane oligopeptide that allows the anchorage of the cytokine molecule to a cell membrane, with the proviso that said chimeric protein does not comprise IL-2 linked to a glycoinositol phospholipid, IL-12 linked to the costimulatory molecule CD80 (B7.1) or IL-15 linked to IL-15 RA.
- a polynucleotide encoding a certain self-aggregating TNFR polypeptide may also encode for additional different self-aggregating members of the TNFR family, e.g. but not limited to, self-aggregating CD40 and self- aggregating 4- 1BB.
- a polynucleotide encoding a membrane bound cytokine may also encode for additional membrane bound cytokines, e.g., but not limited to, membrane bound IL-2 and membrane bound IL-12.
- the present invention is directed to a polynucleotide encoding a chimeric protein comprising a cytokine linked through its carboxyl terminus via a flexible bridge peptide to an integral membrane or transmembrane oligopeptide that allows the anchorage of the cytokine molecule to a cell membrane, with the proviso that said chimeric protein does not comprise IL-2 linked to a glycoinositol phospholipid, IL-12 linked to the costimulatory molecule CD80 (B7.1) or IL-15 linked to IL-15 RA.
- said cytokine is selected from IL-2, IL-12 or IL-15, and in other embodiments the cytokine is a human cytokine.
- the flexible bridge peptide may comprise an amino acid stretch of about 5 amino acids to about 15 amino acids, preferably 8 amino acids of the membrane-proximal amino acids of human HLA-A2, and in certain embodiments it further comprises the 13 amino acid flexible linker Gly 4 Ser(Gly 3 Ser) 2 (SEQ ID NO: 21).
- the cytokine molecule of the chimeric protein of the present invention is linked to an integral membrane or transmembrane oligopeptide that allows the anchorage of the cytokine to a cell membrane.
- the cytokine may be linked to an oligopeptide which is buried in the lipid bilayer and does not protrude to the other side of the membrane.
- the TNFR, caTLR molecule or cytokine of the present invention could conceivably be anchored by any transmembrane oligopeptide known in the art.
- it may be linked through its amino terminus via a glycosylphosphatidylinositol (GPI)-anchor sequence, such as the GPI-anchor peptide of SEQ ID NO: 22, of the sequence FTLTGLLGTLVTMGLLT (from the protein DAF - complement decay- accelerating factor precursor or CD55 antigen; SWISSProt ID P08174, positions 365-381).
- GPI glycosylphosphatidylinositol
- the transmembrane oligopeptide may be predicted by algorithms.
- transmembrane stretch of amino acids could be any such stretch predicted by the above mentioned algorithm or a different algorithm with similar prediction and assignment ratings.
- the cytokine is linked to a transmembrane oligopeptide
- the transmembrane oligopeptide of HLA-A2 it is, in certain embodiments, the transmembrane oligopeptide of HLA-A2 and it may be linked to the cytoplasmic domain of HLA-A2.
- the cytokine may be linked to, and therefore anchored to the cell membrane by > the transmembrane and cytoplasmic portion of HLA-A2.
- the polynucleotide encodes for a membrane bound interleukin, wherein the polynucleotide comprises the following nucleotide sequences: (a) the sequence of SEQ ID NO: 23 encoding for the transmembrane and cytoplasmic portion of HLA-A2; (b) the sequence of SEQ ID NO: 24 encoding for a bridge peptide of a 21 amino acid spacer to the cell membrane, comprising the 13 amino acid flexible linker Gly 4 Ser(Gly 3 Ser) 2 (SEQ ID NO: 21), followed by the 8 membrane-proximal amino acids of the HLA-A2 connecting peptide with an Xhol restriction site; (c) a sequence encoding for the extracellular domain of a cytokine selected from IL-2, IL-12 or IL-15, wherein: (i) the full human IL-2 and its leader peptide sequence is encoded by the sequence of SEQ ID NO: 25; (ii) the chimeric single
- the polynucleotide encoding the chimeric protein of the present invention is an in vitro transcribed RNA molecule, and it may be polyadenylated, capped or both.
- RNA molecule of the present invention could be synthesized by any method known in the art, such as, but not limited to, transcription of an expression vector comprising the relevant DNA sequence either in a eukaryotic cell or, preferably, in vitro using purified RNA polymerase.
- the present invention provides an expression vector comprising a polynucleotide as defined herein above.
- the expression vector comprises a nucleic acid sequence encoding an RNA molecule in a manner which allows transcription of said nucleic acid sequence in vitro.
- the present invention provides a composition comprising at least one polynucleotide or the expression vector as defined herein above.
- the composition comprises at least one polynucleotide, i.e. a DNA or RNA molecule, comprising a sequence encoding: (a) a chimeric protein comprising a cytoplasmic domain of T cell costimulatory receptor of the TNFR family that is linked to a heterologous polypeptide comprising at least one self-assembly domain, said chimeric peptide being linked to an integral membrane or a transmembrane oligopeptide that allows the anchorage of the chimeric polypeptide to the cell membrane; (b) a chimeric protein comprising a cytoplasmic constitutively active domain of a TLR4 molecule linked through its amino terminus to an integral membrane or transmembrane oligopeptide that allows the anchorage of the TLR4 molecule to the cell membrane, and said transmembrane oligopeptide, if existent, is linked, optionally via a bridge peptide, to a peptide tag or
- the composition comprises polynucleotides encoding for a T cell costimulatory receptor of the TNFR family selected from CD40, CD27, 4-1 BB (CD137), OX40 (CD134), herpesvirus entry mediator (HVEM, TNFRSF14), CD30 or glucocorticoid-induced TNFR-related protein (GITR), or combinations thereof.
- a composition comprising a polynucleotide encoding for a self- aggregating TNFR polypeptide as defined in (a) to (1) may also include combinations of polynucleotides encoding for different self-aggregating members of the TNFR family, e.g.
- compositions comprising a polynucleotide encoding for a membrane bound cytokine as defined in (a) to (1) may also include combinations of polynucleotides encoding for different cytokines, e.g., but not limited to, membrane bound IL-2 and membrane bound IL-12.
- the cytokine encoded by the polynucleotide in the composition is selected from IL-2, IL-12 or IL-15, or combinations thereof.
- the present invention relates to activated T cells expressing at least one chimeric protein encoded by the polynucleotide or the expression vector as defined herein above.
- the activated T cells express (a) a chimeric protein comprising a cytoplasmic domain of T cell costimulatory receptor of the TNFR family that is linked to a heterologous polypeptide comprising at least one self-assembly domain, said chimeric peptide being linked to an integral membrane or a transmembrane oligopeptide that allows the anchorage of the chimeric polypeptide to the cell membrane; (b) a chimeric protein comprising a cytoplasmic constitutively active domain of a TLR4 molecule linked through its amino terminus to an integral membrane or transmembrane oligopeptide that allows the anchorage of the TLR4 molecule to the cell membrane, and said transmembrane oligopeptide, if existent, is linked, optionally via a bridge peptide, to a peptide tag or oligopeptide tag; (c) a chimeric protein comprising an extracellular domain of a cytokine linked through its
- a TLR4 molecule y active domain of a TLR4 molecule;
- a chimeric protein comprising a cytokine linked through its carboxyl terminus via a flexible bridge peptide to a cytoplasmic domain of a self- aggregating T cell costimulatory receptor of the tumor necrosis factor receptor (TNFR) family;
- TNFR tumor necrosis factor receptor
- a combination of (a) and (b) a combination of (a) and (c);
- h a combination of (b) and (c);
- the cells express polynucleotides encoding for a T cell costimulatory receptor of the TNFR family selected from CD40, CD27, 4-1BB (CD137), OX40 (CD134), herpesvirus entry mediator (HVEM, TNFRSF14), CD30 or glucocorticoid-induced TNFR-related protein (GITR), or combinations thereof.
- a cell expressing a self-aggregating TNFR polypeptide as defined in (a) to (1) may also express combinations of polynucleotides encoding for different members of the TNFR family, e.g. but not limited to, self-aggregating CD40 and self- aggregating 4- IBB.
- a cell expressing a membrane bound cytokine as defined in (a) to (1) may also express combinations of polynucleotides encoding for different cytokines, e.g., but not limited to, membrane bound IL-2 and membrane b ound IL-12.
- the cell express a cytokine selected from IL-2, IL-12 or IL-15, or combinations thereof.
- the activated T cells express a chimeric protein comprising a cytoplasmic and transmembrane polypeptide of CD40 that is linked to a yeast GCN4 leucine zipper DNA-binding motif self-assembly domain and/or a chimeric protein comprising a cytoplasmic constitutively active domain of a TLR4 molecule linked through a TLR4 transmembrane oligopeptide that allows the anchorage of the TLR4 molecule to the cell membrane.
- the cytokine is linked to the transmembrane and cytoplasmic portion of HLA-A2.
- the T cells used in the present invention may be autologous T cells that are naturally reactive against a tumor (tumor infiltrating lymphocytes or TILs), tumor-specific T cells isolated from peripheral blood lymphocytes (PBLs) or non-tumor-specific autologous or allogeneic cells genetically reprogrammed to express tumor-reactive TCR or chimeric TCR molecules displaying antibody-like tumor recognition capacity.
- the polypeptide may be a chimeric T cell receptor, a T-body (T-bodies are genetically engineered T cells armed with chimeric receptors whose extracellular recognition unit is comprised of an antibody-derived recognition domain and whose intracellular region is derived from lymphocyte stimulating moiety(ies)), a natural or genetically-modified TCR (Morgan et al., 2006), or a TCR-like antibody optionally fused to a toxin, that is specific to a TAA.
- T-bodies are genetically engineered T cells armed with chimeric receptors whose extracellular recognition unit is comprised of an antibody-derived recognition domain and whose intracellular region is derived from lymphocyte stimulating moiety(ies)
- TCR-like antibody optionally fused to a toxin, that is specific to a TAA.
- Tumor infiltrating CTLs are a mixed population of effector and effector memory cells. These cells, which are highly selective to tumor antigens, are suppressed or at anergic state and do not elicit cytotoxic activity. TIL potentiation is currently a major goal of the immune research.
- the activated T cells are tumor-specific T cells.
- the present invention provides a method for treating cancer, comprising administering to a cancer patient, a therapeutically effective amount of tumor specific activated T cells as defined herein above.
- the T cells may be transfected ex vivo, i.e. the T cells are removed from the patient, transfected with the polynucleotide in a laboratory using standard techniques and then returned to the patient; or in situ, using recent techniques that allow for the transfection of the T cells in the patient's body.
- treating refers to the alleviation, reduction of progression or complete cure of the disease, or to the reduction of symptoms related to or caused by the disease.
- the basic TIL-ACT protocol for the treatment of melanoma includes selected tumor-reactive TILs, employing IFN- ⁇ secretion in response to tumor antigens as readout for specificity.
- TILs are expanded by vigorous TCR stimulation followed by lengthy culturing periods with IL-2, resulting in reduced survivabilit. Difficulties in generating autologous melanoma cultures, failure of cultured TILs to produce IFN- ⁇ and exacerbation of disease during selection contribute to considerable patients' dropout and limit the widespread use of sTIL-ACT.
- the TILs are autologous T cells, in particular tumor infiltrating lymphocytes such as young tumor infiltrating lymphocytes.
- the T cells are directed to tumor cells selected from melanoma, breast cancer; chronic myeloid leukemia; acute lymphoblastic leukemia, Hodgkin's lymphoma, non-Hodgkin's lymphoma, acute myeloid leukemia, chronic lymphocytic leukemia, mature B cell neoplasms, mature T cell and natural killer cell neoplasms; liver, stomach, pancreas, intestine and kidney tumors; or bladder, glandular epithelia, lung squamous cell, gut, prostate, testis, thymus, bone marrow, and lymph nodes carcinomas.
- the present invention further provides methods for preparing activated T cells comprising transfecting the T cells with the polynucleotide, the expression vector or the composition as defined herein above, whereby the polynucleotide is expressed within said T cells, thus obtaining the activated T cells.
- the present invention is directed to a method for propagating T cells, comprising transfecting said T cells with a polynucleotide comprising a sequence encoding a chimeric protein comprising IL-2 linked through its carboxyl terminus via a flexible bridge peptide to an integral membrane or transmembrane oligopeptide that allows the anchorage of the IL-2 molecule to a cell membrane.
- This method which obviates the need for adding soluble cytokines to the T cells in order for the cells to propagate and survive, solves the two-sided problem of systemic IL-2 toxicity and insufficient IL-2 support for cells transferred during ACT.
- the method does not involve contacting the cells with a soluble cytokine, i.e. the cells are grown in the absence of soluble cytokines.
- the present invention also contemplates TLR4-activated T cells, wherein said T-cells are obtained by transfecting T cells with an RNA molecule including a ribonucleotide sequence encoding a chimeric protein comprising a cytoplasmic constitutively active domain of a TLR4 molecule linked through its amino terminus to an integral membrane or transmembrane oligopeptide that allows the anchorage of the TLR4 molecule to a cell membrane, whereby the RNA molecule is expressed within said T cells, thus obtaining the TLR4-activated T cells.
- an RNA molecule including a ribonucleotide sequence encoding a chimeric protein comprising a cytoplasmic constitutively active domain of a TLR4 molecule linked through its amino terminus to an integral membrane or transmembrane oligopeptide that allows the anchorage of the TLR4 molecule to a cell membrane, whereby the RNA molecule is expressed within said T cells, thus obtaining the TLR4
- the present invention further considers nucleic acid molecules that comprise DNA sequences encoding for the caTLR4, self- aggregating TNFRs and membrane bound cytokines, and combinations thereof, operably linked to a promoter.
- Any suitable mammalian expression vector can be used such as, but not limited to, the pCI mammalian expression vectors (Promega, Madison, WI, USA), pCDNA3 expression vectors (Invitrogen, San Diego, CA) and pBJl-Neo.
- the expression vector may also be a plasmid DNA in which the polynucleotide sequence is controlled by a virus, e.g. cytomegalovirus, promoter, or, most preferably, the expression vector is a recombinant viral vector such as, but not limited to, pox virus or adenovirus or adeno-associated viral vector.
- transfection any of the techniques which are available in the art may be used to introduce the recombinant nucleic acid encoding the polypeptide into the antigen presenting cell. These techniques are collectively referred to as transfection herein and include, but are not limited to, transfection with naked or encapsulated nucleic acids, cellular fusion, protoplast fusion, viral infection, cellular efidocytosis of calcium-nucleic acid microprecipitates, fusion with liposomes containing nucleic acids, and electroporation. Choice of suitable vectors for expression is well within the skill of the art. Antigen expression may be determined by any of a variety of methods known in the art, such as immunocytochemistry, ELISA, Western blotting, radioimmunoassay, or protein fingerprinting.
- T cells The activation of T cells is manifested in naive cytotoxic T-lymphocytes (CTLs) by differentiation into effector cells that can kill antigen-bearing target cells using granzymes, perforin and FAS ligand, and can rapidly produce inflammatory cytokines, such as IFNy and TNFa upon TCR ligation and activation.
- CTLs cytotoxic T-lymphocytes
- Type II interferon IFN- ⁇ plays a key role in adaptive immunity to viral and bacterial infections and in the antitumor response.
- IFN- ⁇ functions include the enhancement of antigen presentation by both MHC-I and MHC-II products, suppression of the Thl- antagonistic activities of Th2 cells and promotion of effector CD4 Thl and CD8 T cell differentiation.
- IFN- ⁇ is also known for its anti-proliferative, apoptotic and angiogenic effects, all potentially contributing to its well documented antitumor activity.
- An additional cytokine which is involved in T cell activation is IL-2. This cytokine is released from T cells and bind to a specific T cell IL-2 receptor to further promote the activation and proliferation of T cells in an autocrine fashion.
- effector CTLs can adopt multiple cell fates, such as short-lived effectors or memory precursors.
- Short-lived cells effectors can either become senescent effectors and die by apoptosis in several days, or persist into early memory as short-lived effector memory cells.
- Memory precursors by contrast, are long-lived and can be differentiated into effector memory cells or central memory cells. Although the exhausted cell is depicted as sharing a common effector cell precursor with other cell fates, it is currently unclear at what point during effector cell differentiation this fate branches.
- the TLR-activated CD4 T cells are capable of conferring immune memory to activated CD8 T cells, i.e. the constitutive activation of both CD4 and CD8 T cells by the means of the method of the present invention not only produces armed killer T cells but may also produce memory T cells that are capable of sustaining a prolonged attack on the target cells.
- the marker used herein to measure T cell activation is mainly the measurement of the level of secreted IFN- ⁇ ; however, the level of other markers such as, but not limited to, IL-2, TNFa, granzyme B, perforin and FAS ligand secretion and transcription factor NF- B activity, or combination of markers, for T cell maturation could also be assessed. It should be clear to a person skilled in the art that a CD8 T cell that secretes high levels of IFN- ⁇ is an activated, fully mature CD8 T cell, i.e.
- a cytotoxic T cell also known as TC, CTL, T-Killer cell, cytolytic T cell, or killer T cell
- TC cytotoxic T cell
- CTL CTL
- T-Killer cell cytolytic T cell
- killer T cell a CD4 T cell that secretes high levels of IFN- ⁇
- Thl -cell also known as effector Thl cell or Thl cell
- the phrase "preparing TLR-activated T cells" is used herein to describe the production of T cells exhibiting the hallmarks of a mature phenotype, for example secreting high levels of IFN- ⁇ .
- the activated T cells of the present invention are preferably prepared by transfecting T cells with an RNA molecule encoding constitutively active factors and/or membrane cytokines.
- ACT procedures which require the genetic reprogramming of human T cells utilize either retroviral or lentiviral vectors.
- retroviral or lentiviral vectors the clinical implementation of such vectors entails complicated and lengthy procedures, while the number and size of genes that can be introduced is restricted.
- the use of these vectors in the clinic raises serious safety concerns which further limit their wide application.
- mRNA should only gain entry into the cell cytoplasm where it is ready for translation, thus requiring milder transfection conditions; the introduced RNA is similar in composition to the endogenous mRNA and does not carry any inherent danger signals; pre-defined mixtures of mRNA can be easily prepared and introduced simultaneously, rendering this approach highly versatile; andj mRNA offers maximal safety.
- mRNA may not be the ideal vehicle for conferring durable tumor specificity through the transfer of anti-tumor TCR or T-body genes. Nonetheless, this consideration is irrelevant to other ACT approaches which utilize T cells that are naturally reactive against the tumor (TILs, membrane-capturing, allogeneic and T cells activated by tumor or tumor antigens ex-vivo). In contrast, modification of the functional status of T cells (and other immune cells) is usually accomplished in the course of a natural immune response following a transient, rather than a constitutive, stimulus.
- peptide as used herein refers to a short amino acid stretch of between 2 and about 10 amino acids and the term oligopeptide as herein refers to a short amino acid stretch of between 2 and about 20 amino acids.
- oligopeptide refers to a short amino acid stretch of between 2 and about 20 amino acids.
- the term "about” as used herein refers to a maximum deviation of ⁇ 10% from the value preceded by this term.
- RNA preparation and transfection of DCs and APC clones Genes of interest were cloned into the multiple cloning site of a special vector designed for in-vitro production of mRNA ⁇ pEGM4Z/GFP/A64 ⁇ , following removal of the GFP gene.
- This vector described in detail in Boczkowski et al., 2000. Cancer Res 60:1028-1034, is based on the vector pGEM4Z (Promega, Madison, WI).
- Messenger RNA was prepared from cloned templates using the AmpliCap-Max T7 High Yield Massange Marker Kit (Epicenter) following plasmid linearization with Spel.
- Immature and mature DCs were harvested and washed two times in cold PBS, then resuspended in cold Opti-MEM at 2-3 xl06 cells/100 ⁇ and were mixed in 2 mm gap cuvette (Bio-Rad) along with 5-10 Dg of in-vitro transcribed mRNA . The mixture was then subjected to appropriate conditions in a square wave electroporator (BTX-ECM 830,San Diego, CA).
- Example 2 Expression via mRNA transfection of caTLR4, but not caTLR2, potently activates human CD4 and CD8 T cells to secrete IFN- ⁇ .
- Cells were separated by CD4 magnetic beads (BD IMag anti-human CD4 particles) positive selection, grown for additional 24 hours in the presence of 0.5 ⁇ g/ml each anti-CD3 and anti-CD28 mAbs and subjected to electroporation with 5 /ig mRNA using a square- wave pulse at 400 V, 0.95 msec in 0.1 ml in 2 mm cuvettes.
- Control cells were either non-treated (NT), incubated in the presence of LPS or Pam3 (1 ig ml each) or transfected with EGFP-encoding mRNA as a negative control. Secretion of IFN- ⁇ the growth medium was monitored by ELISA (R&D systems Human IFN-gamma Duo Set Economy Pack) 24 h post-transfection.
- the caTLR4 constructs we used in the last experiment encode an HLA-A2- binding tumor- associated peptide linked to ⁇ 2 ⁇ , while the donor was HLA-A2+.
- caTLR4 is active in CD4 and CDS T cells of both donors.
- a Melan-A27- 35/HLA-A2-specific CTL clone, 1C9 isolated from a human melanoma patient by tetramer sorting, were thawed and incubated in culture medium and 6000 u/ml IL-2 was added every 2 days (for the method of tetramer sorting, see for example Ogg and McMichael (1998) Current Opinion in Immunology, 10: 393-396). Electroporation was preformed 5 days post thawing. TIL 122, isolated from a human melanoma tumor, were thawed and incubated for 2 days in culture medium containing 6000 u ml IL-2.
- CD4 positive magnetic beads separation was preformed (BD IMag anti-human CD4 particles). After separation the cells were incubated in 6 ml culture medium and 6000 u/ml IL-2 was added every 2 days. Electroporation was preformed 7 days post thawing. After the electroporation the cells were incubated in 12 well-plates in 3 ml culture medium in the absence of IL-2. 24 h later the supernatant was collected and IFN-7 was measured using R&D systems' Human IFN-gamma DuoSet Economy Pack.
- IL-2Ra CD25
- CD69 elevation is linked to the effector phenotype of CTLs and was reported as an activation marker following CTL incubation with the TLR2 ligand, Pam3.
- Example 3 Generation of constitutively active oligomeric CD40 (caCD40) based on the yeast leucine zipper motif GCN4,
- DCs In order to gain full CD8 T cell priming capacity, DCs must complete their maturation and secrete IL-12. Acquisition of this capacity requires initial triggering of the DC via TLRs (or other innate pathogen-recognition receptors), followed by licensing signals mediated by the engagement of trimeric CD40 ligand (CD40L) at the surface of activated Thl cell with the DC CD40 receptor.
- TLRs or other innate pathogen-recognition receptors
- CD40L trimeric CD40 ligand
- primers for PCR-mediated cloning having the following sequences: For the dimers, primers 1 133 and 1134 of SEQ ID NO: 30 and 31, respectively; for the trimers, primers 1135 and 1136 of SEQ ID NO: 32 and 33, respectively; and for the tetramers, primers 1137 and 1138 of SEQ ID NOs: 34 and 35, respectively.
- primers 1 128 and 1 129 having the sequences of SEQ ID NOs: 36 and 37, respectively, were used.
- Example 4 Generation of membrane bound cytokines and characterization of their activity in transtransfected T cells alone or in combination with caTLR4 or caCD40.
- These chimeric genes comprises the sequence of SEQ ID NO: 23 encoding for the transmembrane and cytoplasmic portion of HLA-A2 and the sequence of SEQ ID NO: 24 encoding for a bridge peptide;
- IL-2 the full human IL-2 and its leader peptide sequence is encoded by the sequence of SEQ ID NO: 25;
- the chimeric single chain derivative of human IL-12 is encoded by the sequence of SEQ ID NO: 26 encoding for the full human IL-12 p40, including the leader peptide, the sequence of SEQ ID NO: 27 encoding for the linker peptide, and the sequence of SEQ ID NO: 28 encoding for the human IL-12 p35 without the leader peptide (see Fig. 7); and
- chimeric human IL-15 is encoded by SEQ ID NO: 5 encoding for the leader peptide of human j8 2 m, and SEQ ID NO: 29 encoding for the mature peptide of human IL-15.
- SEQ ID NO: 5 encoding for the leader peptide of human j8 2 m
- SEQ ID NO: 29 encoding for the mature peptide of human IL-15.
- Membranal (mem) IL-2, IL-12 and IL-15 are designed with a flexible spacer so as to engage its cell surface receptor in-cis (that is, on the same cell).
- CD 8 T cells from PBLs of a healthy donor, were grown for 4 days in O T3 and IL-2 and separated to CD8 and CD4 T cells (O T3 (Janssen-Cilag, or collected from a hybndoma available in our lab) is a mouse monoclonal that binds to and blocks function of T lymphocytes responsible for antigen recognition) Thereafter, the cells were electroporated with memIL-2 and irrelevant mRNA(s) or treated as indicated (Fig. 8).
- CFSE carboxyfluorescein succinimidyl ester
- melanoma TILs were thawed and grown in complete medium in the presence of 2,000 U/ml IL-2.
- Four days post-thawing cells were electroporated with 10 /zg of each mRNA.
- 24 hours post-transfection growth medium was collected for IFN- ⁇ ELISA.
- Fig 9 shows that memIL-2, memIL-12 and caCD40 work synergistically with caTLR4, as can be seen by the tremendous increase in secreted IFN- ⁇ .
- caCD40 and to a lesser extent, caTLR4 are capable of activating the TILs alone.
- M427 is a primary melanoma cells that are recognized by its autologous TIL- 425. Although these cells recognize its target, they are considered exhausted and exhibit very low killing activity.
- TIL-425 were thawed and cultured with 3000 u/ml IL-2 for 4 days. The cells were grown for an additional 3 days to wash out the direct mRNA effect (measured by IFN- ⁇ production). Thereafter 1X10 5 cells were incubated at 1/1 ratio with its targets melanoma cells for 5 hrs. The Ml 71 melanoma cells served as a negative control.
- Example 5 ACT using tumor-specific T cells expressing membranal cytokines, caTNFR or caTLR4, or their combinations.
- mice are used for comparative evaluation of T cell tumoricidal activity in-vivo, using a transplantable human melanoma.
- human melanoma cell line 624mel For this purpose we utilize the human melanoma cell line 624mel. Briefly, male CDlnu/nu mice are injected s.c. in the upper back with lxlO 6 624mel mlanoma cells admixed 1 :1 with Matrigel. Five days later mice are divided into groups of ten and each mouse is injected in the tumor area or IV with lxlO 6 624mel- reactive CD8 T cells cloned from anti-melanoma TILs.
- T cells from each group Prior to injection, all T cells from each group (>10 l0 6 ) will be electroporated in a single cuvette with the respective in- vitro transcribed mRNA under investigation, or irrelevant mRNA as control and then divided for cell transfer. Additional control groups receive none-modified T cells or no T cells. Mice are injected with 1,000 units IL-2 into the tumor site twice daily for 5 days and survival is monitored daily.
- the in-vitro transcribed mRNA tested in this experiment encode for caTLR4, caCD40, caCD27, ca4-lBB (CD137), caOX40 (CD134), caHVEM, caCD30 and caGITR as well as mem IL-2, memIL-12 and memIL-15. Also T cells transfected with combinations thereof will be used. First, caTLR4, caCD40 and mem-IL2 expressing T cells will be examined, and later other combinations.
- Besser M. J., R. Shapira-Frommer, A. J. Treves, D. Zippel, O. Itzhaki, E. Schallmach, A. Kubi, B. Shalmon, I. Hardan, R. Catane, E. Segal, G. Markel, S. Apter, A.
Abstract
L'invention concerne des polynucléotides codant pour des protéines chimériques comprenant le TLR4 constitutivement actif, un élément constitutivement actif du récepteur de costimulation des lymphocytes T de la famille du récepteur du facteur de nécrose tumorale (TNFR) ou d'une cytokine liée à la membrane, ou des combinaisons de ceux-ci. Les polynucléotides sont utiles pour la transfection des lymphocytes T et ainsi les propagent sans avoir besoin de cytokines solubles pour activer constitutivement les lymphocytes T et pour le transfert cellulaire des lymphocytes T constitutivement activés dans le traitement du cancer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161466617P | 2011-03-23 | 2011-03-23 | |
US61/466,617 | 2011-03-23 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2012127464A2 true WO2012127464A2 (fr) | 2012-09-27 |
WO2012127464A3 WO2012127464A3 (fr) | 2013-03-07 |
Family
ID=46051706
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IL2012/000125 WO2012127464A2 (fr) | 2011-03-23 | 2012-03-22 | Lymphocytes t constitutivement activés pour l'utilisation dans une thérapie cellulaire adoptive |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2012127464A2 (fr) |
Cited By (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014055771A1 (fr) * | 2012-10-05 | 2014-04-10 | The Trustees Of The University Of Pennsylvania | Récepteur d'antigène chimérique de récepteur alpha du folate humain |
US8906682B2 (en) | 2010-12-09 | 2014-12-09 | The Trustees Of The University Of Pennsylvania | Methods for treatment of cancer |
WO2015095895A1 (fr) * | 2013-12-20 | 2015-06-25 | Fred Hutchinson Cancer Research Center | Molécules effectrices chimériques marquées et leurs récepteurs |
WO2015143328A1 (fr) * | 2014-03-20 | 2015-09-24 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Lymphocytes infiltrant les tumeurs pour thérapie cellulaire adoptive |
US9394368B2 (en) | 2013-02-20 | 2016-07-19 | Novartis Ag | Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptor |
US9573988B2 (en) | 2013-02-20 | 2017-02-21 | Novartis Ag | Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells |
EP3104866A4 (fr) * | 2014-02-14 | 2017-08-02 | Bellicum Pharmaceuticals, Inc. | Méthodes d'activation des lymphocytes t à l'aide d'un polypeptide chimère inductible |
US9745368B2 (en) | 2013-03-15 | 2017-08-29 | The Trustees Of The University Of Pennsylvania | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
EP3096774A4 (fr) * | 2014-01-21 | 2017-09-06 | Albert Einstein College of Medicine, Inc. | Plate-forme cellulaire d'immunosurveillance rapide et complète des lymphocytes t |
US9777061B2 (en) | 2014-07-21 | 2017-10-03 | Novartis Ag | Treatment of cancer using a CD33 chimeric antigen receptor |
US9815901B2 (en) | 2014-08-19 | 2017-11-14 | Novartis Ag | Treatment of cancer using a CD123 chimeric antigen receptor |
US9896441B2 (en) | 2014-05-05 | 2018-02-20 | Lycera Corporation | Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease |
WO2018044888A1 (fr) * | 2016-08-29 | 2018-03-08 | Chen James C | Systèmes, dispositifs et procédés de vaccination de tumeur |
US9944690B2 (en) | 2013-03-14 | 2018-04-17 | Bellicum Pharmaceuticals, Inc. | Methods for controlling T cell proliferation |
WO2018232296A1 (fr) * | 2017-06-16 | 2018-12-20 | Sangamo Therapeutics, Inc. | Interruption ciblée de récepteurs de lymphocytes t et/ou de hla |
US10174095B2 (en) | 2014-07-21 | 2019-01-08 | Novartis Ag | Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptor |
US10189777B2 (en) | 2014-05-05 | 2019-01-29 | Lycera Corporation | Benzenesulfonamido and related compounds for use as agonists of RORγ and the treatment of disease |
US10221245B2 (en) | 2013-03-16 | 2019-03-05 | Novartis Ag | Treatment of cancer using humanized anti-CD19 chimeric antigen receptor |
US10253086B2 (en) | 2015-04-08 | 2019-04-09 | Novartis Ag | CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cell |
US10273300B2 (en) | 2014-12-29 | 2019-04-30 | The Trustees Of The University Of Pennsylvania | Methods of making chimeric antigen receptor-expressing cells |
US10287354B2 (en) | 2013-12-20 | 2019-05-14 | Novartis Ag | Regulatable chimeric antigen receptor |
US10357514B2 (en) | 2014-04-07 | 2019-07-23 | The Trustees Of The University Of Pennsylvania | Treatment of cancer using anti-CD19 Chimeric Antigen Receptor |
US10421751B2 (en) | 2015-05-05 | 2019-09-24 | Lycera Corporation | Dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease |
WO2019200013A1 (fr) * | 2018-04-11 | 2019-10-17 | Cancer Targeting Systems, Inc. | Combinaisons thérapeutiques pour le traitement du cancer |
WO2019199994A1 (fr) * | 2018-04-11 | 2019-10-17 | Cancer Targeting Systems, Inc. | Constructions thérapeutiques pour le traitement du cancer |
US10525083B2 (en) | 2016-10-07 | 2020-01-07 | Novartis Ag | Nucleic acid molecules encoding chimeric antigen receptors comprising a CD20 binding domain |
US10532088B2 (en) | 2014-02-27 | 2020-01-14 | Lycera Corporation | Adoptive cellular therapy using an agonist of retinoic acid receptor-related orphan receptor gamma and related therapeutic methods |
US10568947B2 (en) | 2014-07-21 | 2020-02-25 | Novartis Ag | Treatment of cancer using a CLL-1 chimeric antigen receptor |
US10577417B2 (en) | 2014-09-17 | 2020-03-03 | Novartis Ag | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
US10611740B2 (en) | 2015-06-11 | 2020-04-07 | Lycera Corporation | Aryl dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease |
US10640569B2 (en) | 2013-12-19 | 2020-05-05 | Novartis Ag | Human mesothelin chimeric antigen receptors and uses thereof |
US10774388B2 (en) | 2014-10-08 | 2020-09-15 | Novartis Ag | Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof |
US10829735B2 (en) | 2015-07-21 | 2020-11-10 | The Trustees Of The University Of Pennsylvania | Methods for improving the efficacy and expansion of immune cells |
US10888608B2 (en) | 2014-09-02 | 2021-01-12 | Bellicum Pharmaceuticals, Inc. | Costimulation of chimeric antigen receptors by MyD88 and CD40 polypeptides |
US10927158B2 (en) | 2016-12-22 | 2021-02-23 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
US10927161B2 (en) | 2017-03-15 | 2021-02-23 | Cue Biopharma, Inc. | Methods for modulating an immune response |
US11028143B2 (en) | 2014-01-21 | 2021-06-08 | Novartis Ag | Enhanced antigen presenting ability of RNA CAR T cells by co-introduction of costimulatory molecules |
US11111493B2 (en) | 2018-03-15 | 2021-09-07 | KSQ Therapeutics, Inc. | Gene-regulating compositions and methods for improved immunotherapy |
US11161907B2 (en) | 2015-02-02 | 2021-11-02 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
US11226339B2 (en) | 2012-12-11 | 2022-01-18 | Albert Einstein College Of Medicine | Methods for high throughput receptor:ligand identification |
US11339201B2 (en) | 2016-05-18 | 2022-05-24 | Albert Einstein College Of Medicine | Variant PD-L1 polypeptides, T-cell modulatory multimeric polypeptides, and methods of use thereof |
US11413340B2 (en) | 2015-12-22 | 2022-08-16 | Novartis Ag | Mesothelin chimeric antigen receptor (CAR) and antibody against PD-L1 inhibitor for combined use in anticancer therapy |
US11459390B2 (en) | 2015-01-16 | 2022-10-04 | Novartis Ag | Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor |
US11505591B2 (en) | 2016-05-18 | 2022-11-22 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
US11512287B2 (en) | 2017-06-16 | 2022-11-29 | Sangamo Therapeutics, Inc. | Targeted disruption of T cell and/or HLA receptors |
US11535662B2 (en) | 2017-01-26 | 2022-12-27 | Novartis Ag | CD28 compositions and methods for chimeric antigen receptor therapy |
US11542488B2 (en) | 2014-07-21 | 2023-01-03 | Novartis Ag | Sortase synthesized chimeric antigen receptors |
US11549099B2 (en) | 2016-03-23 | 2023-01-10 | Novartis Ag | Cell secreted minibodies and uses thereof |
US11608382B2 (en) | 2018-06-13 | 2023-03-21 | Novartis Ag | BCMA chimeric antigen receptors and uses thereof |
US11667691B2 (en) | 2015-08-07 | 2023-06-06 | Novartis Ag | Treatment of cancer using chimeric CD3 receptor proteins |
US11702461B2 (en) | 2018-01-09 | 2023-07-18 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides comprising reduced-affinity immunomodulatory polypeptides |
US11747346B2 (en) | 2015-09-03 | 2023-09-05 | Novartis Ag | Biomarkers predictive of cytokine release syndrome |
WO2023199961A1 (fr) * | 2022-04-14 | 2023-10-19 | 第一三共株式会社 | Polynucléotide codant pour une cytokine de type membrane et un domaine intracellulaire de molécule de la superfamille des récepteurs du tnf |
US11827904B2 (en) | 2015-04-29 | 2023-11-28 | Fred Hutchinson Cancer Center | Modified stem cells and uses thereof |
US11851659B2 (en) | 2017-03-22 | 2023-12-26 | Novartis Ag | Compositions and methods for immunooncology |
US11851471B2 (en) | 2017-01-09 | 2023-12-26 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
US11878062B2 (en) | 2020-05-12 | 2024-01-23 | Cue Biopharma, Inc. | Multimeric T-cell modulatory polypeptides and methods of use thereof |
WO2024028881A1 (fr) * | 2022-08-03 | 2024-02-08 | Migal Galilee Research Institute Ltd. | Cytokines liées à la membrane chimériques incorporant des éléments co-stimulateurs pour améliorer la fonction anti-inflammatoire |
US11896614B2 (en) | 2015-04-17 | 2024-02-13 | Novartis Ag | Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001091698A2 (fr) | 2000-06-01 | 2001-12-06 | Gavish Galilee Bio Appl Ltd | Molecules du cmh genetiquement modifiees |
WO2003106616A2 (fr) | 2002-06-12 | 2003-12-24 | Gavish-Galilee Bio Applications Ltd | $g(b)2 microglobuline ancree sur membrane liee de façon covalente a des epitopes peptidiques du cmh de classe i |
WO2008041231A2 (fr) | 2006-10-03 | 2008-04-10 | Gavish-Galilee Bio Applications Ltd | MICROGLOBULINE β2 ANCRÉE À UNE MEMBRANE, LIÉE DE FAÇON COVALENTE À DES DÉTERMINANTS ANTIGÉNIQUES PEPTIDIQUES MHC CLASSE I |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5716805A (en) * | 1991-10-25 | 1998-02-10 | Immunex Corporation | Methods of preparing soluble, oligomeric proteins |
-
2012
- 2012-03-22 WO PCT/IL2012/000125 patent/WO2012127464A2/fr active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001091698A2 (fr) | 2000-06-01 | 2001-12-06 | Gavish Galilee Bio Appl Ltd | Molecules du cmh genetiquement modifiees |
WO2003106616A2 (fr) | 2002-06-12 | 2003-12-24 | Gavish-Galilee Bio Applications Ltd | $g(b)2 microglobuline ancree sur membrane liee de façon covalente a des epitopes peptidiques du cmh de classe i |
US20080286312A1 (en) | 2002-06-12 | 2008-11-20 | Gavish-Galilee Bio Applications Ltd. | Membrane-anchored beta2 microglobulincovalently linked to MHC class I peptide epitopes |
WO2008041231A2 (fr) | 2006-10-03 | 2008-04-10 | Gavish-Galilee Bio Applications Ltd | MICROGLOBULINE β2 ANCRÉE À UNE MEMBRANE, LIÉE DE FAÇON COVALENTE À DES DÉTERMINANTS ANTIGÉNIQUES PEPTIDIQUES MHC CLASSE I |
Non-Patent Citations (34)
Title |
---|
"Current Protocols in Molecular Biology" |
ASPRODITES, N.; L. ZHENG; D. GENG; C. VELASCO-GONZALEZ; L. SANCHEZ-PEREZ; E. DAVILA: "Engagement of Toll-like receptor-2 on cytotoxic T-lymphocytes occurs in vivo and augments antitumor activity", FASEB J, vol. 22, 2008, pages 3628 - 3637 |
BESSER, M. J.; R. SHAPIRA-FROMMER; A. J. TREVES; D. ZIPPEL; O. ITZHAKI; E. SCHALLMACH; A. KUBI; B. SHALMON; I. HARDAN; R. CATANE: "Minimally cultured or selected autologous tumor-infiltrating lymphocytes after a lympho-depleting chemotherapy regimen in metastatic melanoma patients", J IMMUNOTHER, vol. 32, 2009, pages 415 - 423 |
BESSER, M. J.; R. SHAPIRA-FROMMER; A. J. TREVES; D. ZIPPEL; O. ITZHAKI; L. HERSHKOVITZ; D. LEVY; A. KUBI; E. HOVAV; N. CHERMOSHNIU: "Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients", CLIN CANCER RES, vol. 16, 2010, pages 2646 - 2655 |
BOCZKOWSKI ET AL., CANCER RES, vol. 60, 2000, pages 1028 - 1034 |
CARON, G.; D. DULUC; I. FREMAUX; P. JEANNIN; C. DAVID; H. GASCAN; Y. DELNESTE: "Direct stimulation of human T cells via TLR5 and TLR7/8: flagellin and R-848 up-regulate proliferation and IFN-gamma production by memory CD4+ T cells", J IMMUNOL, vol. 175, 2005, pages 1551 - 1557, XP002712773, DOI: doi:10.4049/jimmunol.175.3.1551 |
CHAKRABARTI, R.; Y. CHANG; K. SONG; G. J. PRUD'HOMME: "Plasmids encoding membrane-bound IL-4 or IL-12 strongly costimulate DNA vaccination against carcinoembryonic antigen (CEA", VACCINE, vol. 22, 2004, pages 1199 - 1205, XP004493383, DOI: doi:10.1016/j.vaccine.2003.09.023 |
COTTALORDA, A.; C. VERSCHELDE; A. MARCAIS; M. TOMKOWIAK; P. MUSETTE; S. UEMATSU; S. AKIRA; J. MARVEL; N. BONNEFOY-BERARD: "TLR2 engagement on CD8 T cells lowers the threshold for optimal antigen-induced T cell activation", EUR J IMMUNOL, vol. 36, 2006, pages 1684 - 1693 |
DUDLEY, M. E.; C. A. GROSS; M. M. LANGHAN; M. R. GARCIA; R. M. SHERRY; J. C. YANG; G. Q. PHAN; U. S. KAMMULA; M. S. HUGHES; D. E.: "CD8+ enriched ''young'' tumor infiltrating lymphocytes can mediate regression of metastatic melanoma", CLIN CANCER RES, vol. 16, 2010, pages 6122 - 6131 |
GARCI'A-SANZ, N.; ASIA FERNA'NDEZ-CARVAJAL; CRUZ MORENILLA-PALAO; ROSA PLANELLS-CASES; EMMANUEL FAJARDO-SA'NCHEZ; GREGORIO FEMA'ND: "Identification of a Tetramerization Domain in the C Terminus of the Vanilloid Receptor", THE JOURNAL OF NEUROSCIENCE, vol. 24, no. 23, 2004, pages 5307 - 5314 |
HARBURY PB; TIDOR B; KIM PS: "Repacking protein cores with backbone freedom: structure prediction for coiled coils", PROC NATL ACAD SCI USA., vol. 92, no. 18, 1995, pages 8408 - 12 |
HARBURY PB; ZHANG T; KIM PS; ALBER T.: "A switch between two-, three-, and four-stranded coiled coils in GCN4 leucine zipper mutants", SCIENCE, vol. 262, no. 5138, 26 December 1992 (1992-12-26), pages 1401 - 7, XP000941971, DOI: doi:10.1126/science.8248779 |
HASAN, U. A.; S. DOLLET; J. VLACH.: "Differential induction of gene promoter constructs by constitutively active human TLRs", BIOCHEM BIOPHYS RES COMMUN, vol. 321, 2004, pages 124 - 131, XP004521407, DOI: doi:10.1016/j.bbrc.2004.06.134 |
HSU, C.; M. S. HUGHES; Z. ZHENG; R. B. BRAY; S. A. ROSENBERG; R. A. MORGAN: "Primary human T lymphocytes engineered with a codon-optimized IL-15 gene resist cytokine withdrawal-induced apoptosis and persist long-term in the absence of exogenous cytokine", J IMMUNOL, vol. 175, 2005, pages 7226 - 7234, XP002435509 |
IMANISHI, T.; H. HARA; S. SUZUKI; N. SUZUKI; S. AKIRA; T. SAITO: "Cutting edge: TLR2 directly triggers Th1 effector functions", J IMMUNOL, vol. 178, 2007, pages 6715 - 6719 |
ITZHAKI, O.; E. HOVAV; Y. ZIPOREN; D. LEVY; A. KUBI; D. ZIKICH; L. HERSHKOVITZ; A. J. TREVES; B. SHALMON; D. ZIPPEL: "Establishment and large-scale expansion of minimally cultured ''young'' tumor infiltrating lymphocytes for adoptive transfer therapy", J IMMUNOTHER, vol. 34, 2011, pages 212 - 220 |
JI, J.; J. LI; L. M. HOLMES; K. E. BURGIN; X. YU; T. E. WAGNER; Y. WEI: "Glycoinositol phospholipid-anchored interleukin 2 but not secreted interleukin 2 inhibits melanoma tumor growth in mice", MOL CANCER THER, vol. 1, 2002, pages 1019 - 1024 |
KLEBANOFF, C. A.; S. E. FINKELSTEIN; D. R. SURMAN; M. K. LICHTMAN; L. GATTINONI; M. R. THEORET; N. GREWAL; P. J. SPIESS; P. A. ANT: "IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells", PROC NATL ACAD SCI U S A, vol. 101, 2004, pages 1969 - 1974, XP002607147, DOI: doi:10.1073/pnas.0307298101 |
KOMAI-KOMA, M.; L. JONES; G. S. OGG; D. XU; F. Y. LIEW: "TLR2 is expressed on activated T cells as a costimulatory receptor", PROC NATL ACAD SCI U S A, vol. 101, 2004, pages 3029 - 3034, XP055031568, DOI: doi:10.1073/pnas.0400171101 |
LEE, Y. L.; M.. H. TAO; Y. H. CHOW; B. L. CHIANG: "Construction of vectors expressing bioactive heterodimeric and single-chain murine interleukin-12 for gene therapy", HUM GENE THER, vol. 9, 1998, pages 457 - 465, XP009036800 |
LIU, H.; M. KOMAI-KOMA; D. XU; F. Y. LIEW: "Toll-like receptor 2 signaling modulates the functions of CD4+ CD25+ regulatory T cells", PROC NATL ACAD SCI U S A, vol. 103, 2006, pages 7048 - 7053 |
LODE, H. N.; T. DREIER; R. XIANG; N. M. VARKI; A. S. KANG; R. A. REISFELD: "Gene therapy with a single chain interleukin 12 fusion protein induces T cell- dependent protective immunity in a syngeneic model of murine neuroblastoma", PROC NATL ACAD SCI U S A, vol. 95, 1998, pages 2475 - 2480, XP002943730, DOI: doi:10.1073/pnas.95.5.2475 |
MEDZHITOV, R.; P. PRESTON-HURLBURT; C. A. JANEWAY, JR.: "A human homologue of the Drosophila Toll protein signals activation of adaptive immunity", NATURE, vol. 388, 1997, pages 394 - 397, XP002099039, DOI: doi:10.1038/41131 |
MILLER M: "The Importance of Being Flexible: The Case of Basic Region Leucine Zipper Transcriptional Regulators", CURRENT PROTEIN AND PEPTIDE SCIENCE, vol. 10, 2009, pages 244 - 269 |
MORGAN, R. A.; M. E. DUDLEY; J. R. WUNDERLICH; M. S. HUGHES; J. C. YANG; R. M. SHERRY; R. E. ROYAL; S. L. TOPALIAN; U. S. KAMMULA;: "Cancer regression in patients after transfer of genetically engineered lymphocytes", SCIENCE, vol. 314, 2006, pages 126 - 129, XP002478784, DOI: doi:10.1126/science.1129003 |
OGG; MCMICHAEL, CURRENT OPINION IN IMMUNOLOGY, vol. 10, 1998, pages 393 - 396 |
OZINSKY, A.; D. M. UNDERHILL; J. D. FONTENOT; A. M. HAJJAR; K. D. SMITH; C. B. WILSON; L. SCHROEDER; A. ADEREM: "The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between toll-like receptors", PROC NATL ACAD SCI U S A, vol. 97, 2000, pages 13766 - 13771, XP002976690, DOI: doi:10.1073/pnas.250476497 |
PASQUIER; HAMODRAKAS: "An hierarchical artificial neural network system for the classification of transmembrane proteins", PROTEIN ENG, vol. 12, no. 8, August 1999 (1999-08-01), pages 631 - 4 |
QUINTARELLI, C.; J. F. VERA; B. SAVOLDO; G. M. GIORDANO ATTIANESE; M. PULE; A. E. FOSTER; H. E. HESLOP; C. M. ROONEY; M. K. BRENNE: "Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes", BLOOD, vol. 110, 2007, pages 2793 - 2802 |
SCHNEIDER, D. S.; K. L. HUDSON; T. Y. LIN; K. V. ANDERSON: "Dominant and recessive mutations define functional domains of Toll, a transmembrane protein required for dorsal-ventral polarity in the Drosophila embryo", GENES DEV, vol. 5, 1991, pages 797 - 807 |
TABIASCO, J.; E. DEVEVRE; N. RUFER; B. SALAUN; J. C. CEROTTINI; D. SPEISER; P. ROMERO: "Human effector CD8+ T lymphocytes express TLR3 as a functional coreceptor", J IMMUNOL, vol. 177, 2006, pages 8708 - 8713 |
TESTA, OD; E. MOUTEVELIS; D.N. WOOLFSON, NUCLEIC ACIDS RESEARCH, vol. 37, 2009, pages D315 - D322 |
TIJSSEN: "Techniques in Biochemistry and Molecular BiologyHybridization with Nucleic Probes", 1993, article "Overview of principles of hybridization and the strategy of nucleic acid assays" |
TRAN, K. Q.; J. ZHOU; K. H. DURFLINGER; M. M. LANGHAN; T. E. SHELTON; J. R. WUNDERLICH; P. F. ROBBINS; S. A. ROSENBERG; M. E. DUDL: "Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapy", J IMMUNOTHER, vol. 31, 2008, pages 742 - 751, XP055031158, DOI: doi:10.1097/CJI.0b013e31818403d5 |
Cited By (123)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9499629B2 (en) | 2010-12-09 | 2016-11-22 | The Trustees Of The University Of Pennsylvania | Use of chimeric antigen receptor-modified T-cells to treat cancer |
US8911993B2 (en) | 2010-12-09 | 2014-12-16 | The Trustees Of The University Of Pennsylvania | Compositions for treatment of cancer |
US9328156B2 (en) | 2010-12-09 | 2016-05-03 | The Trustees Of The University Of Pennsylvania | Use of chimeric antigen receptor-modified T cells to treat cancer |
US8916381B1 (en) | 2010-12-09 | 2014-12-23 | The Trustees Of The University Of Pennyslvania | Methods for treatment of cancer |
US8975071B1 (en) | 2010-12-09 | 2015-03-10 | The Trustees Of The University Of Pennsylvania | Compositions for treatment of cancer |
US9540445B2 (en) | 2010-12-09 | 2017-01-10 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treatment of cancer |
US9102761B2 (en) | 2010-12-09 | 2015-08-11 | The Trustees Of The University Of Pennsylvania | Compositions for treatment of cancer |
US9101584B2 (en) | 2010-12-09 | 2015-08-11 | The Trustees Of The University Of Pennsylvania | Methods for treatment of cancer |
US9518123B2 (en) | 2010-12-09 | 2016-12-13 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treatment of cancer |
US9481728B2 (en) | 2010-12-09 | 2016-11-01 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treatment of cancer |
US9464140B2 (en) | 2010-12-09 | 2016-10-11 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treatment of cancer |
US8906682B2 (en) | 2010-12-09 | 2014-12-09 | The Trustees Of The University Of Pennsylvania | Methods for treatment of cancer |
US9102760B2 (en) | 2010-12-09 | 2015-08-11 | The Trustees Of The University Of Pennsylvania | Compositions for treatment of cancer |
US10844117B2 (en) | 2012-10-05 | 2020-11-24 | The Trustees Of The University Of Pennsylvania | Human alpha-folate receptor chimeric antigen receptor |
WO2014055771A1 (fr) * | 2012-10-05 | 2014-04-10 | The Trustees Of The University Of Pennsylvania | Récepteur d'antigène chimérique de récepteur alpha du folate humain |
US9598489B2 (en) | 2012-10-05 | 2017-03-21 | The Trustees Of The Univeristy Of Pennsylvania | Human alpha-folate receptor chimeric antigen receptor |
US11226339B2 (en) | 2012-12-11 | 2022-01-18 | Albert Einstein College Of Medicine | Methods for high throughput receptor:ligand identification |
US10308717B2 (en) | 2013-02-20 | 2019-06-04 | Novartis Ag | Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptor |
US11865167B2 (en) | 2013-02-20 | 2024-01-09 | Novartis Ag | Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptor |
US11028177B2 (en) | 2013-02-20 | 2021-06-08 | Novartis Ag | Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells |
US9573988B2 (en) | 2013-02-20 | 2017-02-21 | Novartis Ag | Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells |
US9394368B2 (en) | 2013-02-20 | 2016-07-19 | Novartis Ag | Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptor |
US9944690B2 (en) | 2013-03-14 | 2018-04-17 | Bellicum Pharmaceuticals, Inc. | Methods for controlling T cell proliferation |
US10640553B2 (en) | 2013-03-15 | 2020-05-05 | Novartis Ag | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
US9745368B2 (en) | 2013-03-15 | 2017-08-29 | The Trustees Of The University Of Pennsylvania | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
US11919946B2 (en) | 2013-03-15 | 2024-03-05 | Novartis Ag | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
US10927184B2 (en) | 2013-03-16 | 2021-02-23 | Novartis Ag | Treatment of cancer using humanized anti-CD19 chimeric antigen receptor |
US10221245B2 (en) | 2013-03-16 | 2019-03-05 | Novartis Ag | Treatment of cancer using humanized anti-CD19 chimeric antigen receptor |
US10640569B2 (en) | 2013-12-19 | 2020-05-05 | Novartis Ag | Human mesothelin chimeric antigen receptors and uses thereof |
US11578130B2 (en) | 2013-12-20 | 2023-02-14 | Novartis Ag | Regulatable chimeric antigen receptor |
US11046766B2 (en) | 2013-12-20 | 2021-06-29 | Fred Hutchinson Cancer Research Center | Tagged chimeric effector molecules and receptors thereof |
WO2015095895A1 (fr) * | 2013-12-20 | 2015-06-25 | Fred Hutchinson Cancer Research Center | Molécules effectrices chimériques marquées et leurs récepteurs |
CN105980402B (zh) * | 2013-12-20 | 2021-06-15 | 弗雷德哈钦森癌症研究中心 | 带标签的嵌合效应分子及其受体 |
US10287354B2 (en) | 2013-12-20 | 2019-05-14 | Novartis Ag | Regulatable chimeric antigen receptor |
CN105980402A (zh) * | 2013-12-20 | 2016-09-28 | 弗雷德哈钦森癌症研究中心 | 带标签的嵌合效应分子及其受体 |
RU2729463C2 (ru) * | 2013-12-20 | 2020-08-06 | Фред Хатчинсон Кансэр Рисёч Сентер | Меченые химерные эффекторные молекулы и их рецепторы |
US10494434B2 (en) | 2013-12-20 | 2019-12-03 | Fred Hutchinson Cancer Research Center | Tagged chimeric effector molecules and receptors thereof |
US11028143B2 (en) | 2014-01-21 | 2021-06-08 | Novartis Ag | Enhanced antigen presenting ability of RNA CAR T cells by co-introduction of costimulatory molecules |
EP3096774A4 (fr) * | 2014-01-21 | 2017-09-06 | Albert Einstein College of Medicine, Inc. | Plate-forme cellulaire d'immunosurveillance rapide et complète des lymphocytes t |
EP3104866A4 (fr) * | 2014-02-14 | 2017-08-02 | Bellicum Pharmaceuticals, Inc. | Méthodes d'activation des lymphocytes t à l'aide d'un polypeptide chimère inductible |
US10934346B2 (en) | 2014-02-14 | 2021-03-02 | Bellicum Pharmaceuticals, Inc. | Modified T cell comprising a polynucleotide encoding an inducible stimulating molecule comprising MyD88, CD40 and FKBP12 |
US10532088B2 (en) | 2014-02-27 | 2020-01-14 | Lycera Corporation | Adoptive cellular therapy using an agonist of retinoic acid receptor-related orphan receptor gamma and related therapeutic methods |
US11518980B2 (en) | 2014-03-20 | 2022-12-06 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Tumor-infiltrating lymphocytes for adoptive cell therapy |
JP2017511375A (ja) * | 2014-03-20 | 2017-04-20 | エイチ リー モフィット キャンサー センター アンド リサーチ インスティテュート インコーポレイテッド | 養子細胞療法のための腫瘍浸潤リンパ球 |
AU2015231041B2 (en) * | 2014-03-20 | 2020-07-16 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Tumor-infiltrating lymphocytes for adoptive cell therapy |
CN106659913A (zh) * | 2014-03-20 | 2017-05-10 | H.李莫菲特癌症中心研究院 | 用于过继细胞疗法的肿瘤浸润淋巴细胞 |
EA036386B1 (ru) * | 2014-03-20 | 2020-11-03 | Х. Ли Моффитт Кэнсер Сентер Энд Рисёч Инститьют, Инк. | Проникающие в опухоль лимфоциты для адоптивной клеточной терапии |
WO2015143328A1 (fr) * | 2014-03-20 | 2015-09-24 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Lymphocytes infiltrant les tumeurs pour thérapie cellulaire adoptive |
US10357514B2 (en) | 2014-04-07 | 2019-07-23 | The Trustees Of The University Of Pennsylvania | Treatment of cancer using anti-CD19 Chimeric Antigen Receptor |
US10189777B2 (en) | 2014-05-05 | 2019-01-29 | Lycera Corporation | Benzenesulfonamido and related compounds for use as agonists of RORγ and the treatment of disease |
US10442798B2 (en) | 2014-05-05 | 2019-10-15 | Lycera Corporation | Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease |
US10364237B2 (en) | 2014-05-05 | 2019-07-30 | Lycera Corporation | Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease |
US9896441B2 (en) | 2014-05-05 | 2018-02-20 | Lycera Corporation | Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease |
US10568947B2 (en) | 2014-07-21 | 2020-02-25 | Novartis Ag | Treatment of cancer using a CLL-1 chimeric antigen receptor |
US11084880B2 (en) | 2014-07-21 | 2021-08-10 | Novartis Ag | Anti-BCMA chimeric antigen receptor |
US11542488B2 (en) | 2014-07-21 | 2023-01-03 | Novartis Ag | Sortase synthesized chimeric antigen receptors |
US10174095B2 (en) | 2014-07-21 | 2019-01-08 | Novartis Ag | Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptor |
US10851166B2 (en) | 2014-07-21 | 2020-12-01 | Novartis Ag | Treatment of cancer using a CD33 chimeric antigen receptor |
US9777061B2 (en) | 2014-07-21 | 2017-10-03 | Novartis Ag | Treatment of cancer using a CD33 chimeric antigen receptor |
US10703819B2 (en) | 2014-08-09 | 2020-07-07 | The Trustees Of The University Of Pennsylvania | Treatment of cancer using a CD123 chimeric antigen receptor |
US11591404B2 (en) | 2014-08-19 | 2023-02-28 | Novartis Ag | Treatment of cancer using a CD123 chimeric antigen receptor |
US9815901B2 (en) | 2014-08-19 | 2017-11-14 | Novartis Ag | Treatment of cancer using a CD123 chimeric antigen receptor |
US10888608B2 (en) | 2014-09-02 | 2021-01-12 | Bellicum Pharmaceuticals, Inc. | Costimulation of chimeric antigen receptors by MyD88 and CD40 polypeptides |
US10918705B2 (en) | 2014-09-02 | 2021-02-16 | Bellicum Pharmaceutics, Inc. | Costimulation of chimeric antigen receptors by MYD88 and CD40 polypeptides |
US10577417B2 (en) | 2014-09-17 | 2020-03-03 | Novartis Ag | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
US10774388B2 (en) | 2014-10-08 | 2020-09-15 | Novartis Ag | Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof |
US10273300B2 (en) | 2014-12-29 | 2019-04-30 | The Trustees Of The University Of Pennsylvania | Methods of making chimeric antigen receptor-expressing cells |
US11459390B2 (en) | 2015-01-16 | 2022-10-04 | Novartis Ag | Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor |
US11161907B2 (en) | 2015-02-02 | 2021-11-02 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
US10253086B2 (en) | 2015-04-08 | 2019-04-09 | Novartis Ag | CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cell |
US11149076B2 (en) | 2015-04-08 | 2021-10-19 | Novartis Ag | CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cell |
US11896614B2 (en) | 2015-04-17 | 2024-02-13 | Novartis Ag | Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells |
US11827904B2 (en) | 2015-04-29 | 2023-11-28 | Fred Hutchinson Cancer Center | Modified stem cells and uses thereof |
US10421751B2 (en) | 2015-05-05 | 2019-09-24 | Lycera Corporation | Dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease |
US10611740B2 (en) | 2015-06-11 | 2020-04-07 | Lycera Corporation | Aryl dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease |
US11059796B2 (en) | 2015-06-11 | 2021-07-13 | The Regents Of The University Of Michigan | Aryl dihydro-2H benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease |
US10829735B2 (en) | 2015-07-21 | 2020-11-10 | The Trustees Of The University Of Pennsylvania | Methods for improving the efficacy and expansion of immune cells |
US11667691B2 (en) | 2015-08-07 | 2023-06-06 | Novartis Ag | Treatment of cancer using chimeric CD3 receptor proteins |
US11747346B2 (en) | 2015-09-03 | 2023-09-05 | Novartis Ag | Biomarkers predictive of cytokine release syndrome |
US11413340B2 (en) | 2015-12-22 | 2022-08-16 | Novartis Ag | Mesothelin chimeric antigen receptor (CAR) and antibody against PD-L1 inhibitor for combined use in anticancer therapy |
US11549099B2 (en) | 2016-03-23 | 2023-01-10 | Novartis Ag | Cell secreted minibodies and uses thereof |
US11339201B2 (en) | 2016-05-18 | 2022-05-24 | Albert Einstein College Of Medicine | Variant PD-L1 polypeptides, T-cell modulatory multimeric polypeptides, and methods of use thereof |
US11505591B2 (en) | 2016-05-18 | 2022-11-22 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
WO2018044888A1 (fr) * | 2016-08-29 | 2018-03-08 | Chen James C | Systèmes, dispositifs et procédés de vaccination de tumeur |
US11872249B2 (en) | 2016-10-07 | 2024-01-16 | Novartis Ag | Method of treating cancer by administering immune effector cells expressing a chimeric antigen receptor comprising a CD20 binding domain |
USRE49847E1 (en) | 2016-10-07 | 2024-02-27 | Novartis Ag | Nucleic acid molecules encoding chimeric antigen receptors comprising a CD20 binding domain |
US11026976B2 (en) | 2016-10-07 | 2021-06-08 | Novartis Ag | Nucleic acid molecules encoding chimeric antigen receptors comprising a CD20 binding domain |
US10525083B2 (en) | 2016-10-07 | 2020-01-07 | Novartis Ag | Nucleic acid molecules encoding chimeric antigen receptors comprising a CD20 binding domain |
US11851467B2 (en) | 2016-12-22 | 2023-12-26 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
US11505588B2 (en) | 2016-12-22 | 2022-11-22 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
US11117945B2 (en) | 2016-12-22 | 2021-09-14 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
US11370821B2 (en) | 2016-12-22 | 2022-06-28 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
US11739133B2 (en) | 2016-12-22 | 2023-08-29 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
US11530248B2 (en) | 2016-12-22 | 2022-12-20 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
US10927158B2 (en) | 2016-12-22 | 2021-02-23 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
US11905320B2 (en) | 2016-12-22 | 2024-02-20 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
US11401314B2 (en) | 2016-12-22 | 2022-08-02 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
US11377478B2 (en) | 2016-12-22 | 2022-07-05 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
US11708400B2 (en) | 2016-12-22 | 2023-07-25 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
US11851471B2 (en) | 2017-01-09 | 2023-12-26 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
US11535662B2 (en) | 2017-01-26 | 2022-12-27 | Novartis Ag | CD28 compositions and methods for chimeric antigen receptor therapy |
US11104712B2 (en) | 2017-03-15 | 2021-08-31 | Cue Biopharma, Inc. | Methods for modulating an immune response |
US11958893B2 (en) | 2017-03-15 | 2024-04-16 | Cue Biopharma, Inc. | Methods for modulating an immune response |
US10927161B2 (en) | 2017-03-15 | 2021-02-23 | Cue Biopharma, Inc. | Methods for modulating an immune response |
US11479595B2 (en) | 2017-03-15 | 2022-10-25 | Cue Biopharma, Inc. | Methods for modulating an immune response |
US11767355B2 (en) | 2017-03-15 | 2023-09-26 | Cue Biopharma, Inc. | Methods for modulating an immune response |
US11851659B2 (en) | 2017-03-22 | 2023-12-26 | Novartis Ag | Compositions and methods for immunooncology |
US11512287B2 (en) | 2017-06-16 | 2022-11-29 | Sangamo Therapeutics, Inc. | Targeted disruption of T cell and/or HLA receptors |
WO2018232296A1 (fr) * | 2017-06-16 | 2018-12-20 | Sangamo Therapeutics, Inc. | Interruption ciblée de récepteurs de lymphocytes t et/ou de hla |
US11702461B2 (en) | 2018-01-09 | 2023-07-18 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides comprising reduced-affinity immunomodulatory polypeptides |
US11111493B2 (en) | 2018-03-15 | 2021-09-07 | KSQ Therapeutics, Inc. | Gene-regulating compositions and methods for improved immunotherapy |
US11421228B2 (en) | 2018-03-15 | 2022-08-23 | KSQ Therapeutics, Inc. | Gene-regulating compositions and methods for improved immunotherapy |
US11608500B2 (en) | 2018-03-15 | 2023-03-21 | KSQ Therapeutics, Inc. | Gene-regulating compositions and methods for improved immunotherapy |
WO2019199994A1 (fr) * | 2018-04-11 | 2019-10-17 | Cancer Targeting Systems, Inc. | Constructions thérapeutiques pour le traitement du cancer |
WO2019200013A1 (fr) * | 2018-04-11 | 2019-10-17 | Cancer Targeting Systems, Inc. | Combinaisons thérapeutiques pour le traitement du cancer |
US20210154328A1 (en) * | 2018-04-11 | 2021-05-27 | Cancer Targeting System, Inc. | Therapeutic constructs for treating cancer |
US20210155955A1 (en) * | 2018-04-11 | 2021-05-27 | Cancer Targeting Systems, Inc. | Therapeutic constructs for treating cancer |
US11608382B2 (en) | 2018-06-13 | 2023-03-21 | Novartis Ag | BCMA chimeric antigen receptors and uses thereof |
US11939389B2 (en) | 2018-06-13 | 2024-03-26 | Novartis Ag | BCMA chimeric antigen receptors and uses thereof |
US11952428B2 (en) | 2018-06-13 | 2024-04-09 | Novartis Ag | BCMA chimeric antigen receptors and uses thereof |
US11878062B2 (en) | 2020-05-12 | 2024-01-23 | Cue Biopharma, Inc. | Multimeric T-cell modulatory polypeptides and methods of use thereof |
WO2023199961A1 (fr) * | 2022-04-14 | 2023-10-19 | 第一三共株式会社 | Polynucléotide codant pour une cytokine de type membrane et un domaine intracellulaire de molécule de la superfamille des récepteurs du tnf |
WO2024028881A1 (fr) * | 2022-08-03 | 2024-02-08 | Migal Galilee Research Institute Ltd. | Cytokines liées à la membrane chimériques incorporant des éléments co-stimulateurs pour améliorer la fonction anti-inflammatoire |
Also Published As
Publication number | Publication date |
---|---|
WO2012127464A3 (fr) | 2013-03-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2012127464A2 (fr) | Lymphocytes t constitutivement activés pour l'utilisation dans une thérapie cellulaire adoptive | |
US20220169699A1 (en) | Pd-1-cd28 fusion proteins and their use in medicine | |
ES2963718T3 (es) | Capacidad presentadora de antígenos de células CAR-T potenciada mediante introducción conjunta de moléculas co-estimuladoras | |
US20230355677A1 (en) | Tethered interleukin-15 and interleukin-21 | |
US20220380435A1 (en) | Fusion proteins of pd-1 and 4-1bb | |
US20180371052A1 (en) | Chimeric antigen receptors and enhancement of anti-tumor activity | |
JP2022547967A (ja) | Cd40細胞質ドメインを含むキメラ抗原レセプター及びその使用 | |
CN113677352A (zh) | T细胞修饰 | |
CN113416260A (zh) | 靶向Claudin18.2的特异性嵌合抗原受体细胞及其制备方法和应用 | |
KR20210057750A (ko) | 암 면역치료요법을 위한 mr1 제한된 t 세포 수용체 | |
KR20200036874A (ko) | 암 치료를 위한 방법 및 조성물 | |
US20220380433A1 (en) | Tmem59 protein dimer or chimeric expression receptor improving t cell function | |
EP4330377A2 (fr) | Cellules de présentation d'antigène recombinant | |
JP2022525921A (ja) | 免疫エフェクタ細胞の特異的活性化のためのインターロイキン2受容体(il2r)およびインターロイキン2(il2)バリアント | |
US11364267B1 (en) | Bi-specific targeting human NKG2DL and CLDN18A2 chimeric antigen receptor cells, preparation method and application thereof | |
KR20240055714A (ko) | 돌연변이 il-15 조성물 및 이의 방법 | |
WO2023076523A1 (fr) | Polypeptides adaptateurs chimériques | |
CN115151274A (zh) | Hla限制性hormad1 t细胞受体及其用途 | |
TW202102237A (zh) | 於抗原特異性免疫細胞中調控cd160功能的方法及其用途 | |
CN117616116A (zh) | 突变体il-15组合物及其方法 | |
KR20210144737A (ko) | T 세포 수용체 및 이의 사용 방법 | |
CN117120598A (zh) | 激活和增殖暴露于抗原的cd8 t细胞的方法、由此制备的具有增强的抗癌活性的cd8 t细胞及其用途 | |
CN117580870A (zh) | 表达tlr受体的经修饰的免疫细胞 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12720010 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 12720010 Country of ref document: EP Kind code of ref document: A2 |